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General introduction 
 
G protein-coupled receptors (GPCRs) are the largest class of cell-surface receptors, and today 
represent 40% of all drug targets on the pharmaceutical market. In the absence of agonists, 
many GPCRs have been found to exhibit spontaneous activity, which can be blocked by 
ligands that are referred to as inverse agonists (Milligan, 2003). 
The Cannabinoid type 1 (CB1) receptor is one of the most abundant GPCRs in the central 
nervous system (CNS), and is coupled to Gi/o proteins to inhibit adenylyl cyclase, activate 
mitogen-activated protein kinase (MAPK), inhibit voltage gated Ca2+ channels and activate 
inwardly rectifying K+ channels (Howlett et al., 2000, Pertwee 1997). The first selective and 
potent CB1 receptor antagonist Rimonabant (also known SR141716A, SR) at high 
micromolar concentrations behaves as an inverse agonist, i.e. decreases [35S]GTPγS binding 
in the rodent and human cerebral cortex and in Chinese hamster ovary (CHO) cells 
transfected with CB1 receptors (Rinaldi-Carmona et al., 1994). However, in vitro and in vivo 
studies performed using the CB1 receptor knockout (KO) and CHO cells not expressing CB1 
receptors suggest that the inverse agonist activity of SR is CB1 receptor-independent (Pertwee 
et al., 2005). Several hypotheses have been postulated to explain the inverse agonism of SR, 
including its action on different receptors (i.e GPCR mainly coupled to Gi/o proteins) and/or 
its negative modulation of the constitutive activity of CB1 receptors. Alternatively, SR might 
explain this “inverse agonist effect” in a receptor-independent manner by acting directly on G 
protein levels.  
The present study aimed to determine whether the CB1 receptor-independent effects of SR are 
mediated via GPCRs, in particular GABAB and dopamine D2 receptors that share the same 
Gαi/o signaling pathways, or if SR acts directly on G protein subunits. 
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For this purpose, in this thesis, we investigated the molecular mechanisms of SR on G protein 
activity in native and recombinant systems by using different experimental approaches (i.e., 
GTPγS binding, Bioluminescence Resonance Energy Transfer (BRET), electrophysiological 
recordings). In particular, we first evaluated the effects of SR on basal and agonist-stimulated 
[35S]GTPγS binding in systems containing CB1, GABAB and D2 receptor populations (i.e., 
rat membrane homogenates and CHO stable transfected with GABAB or D2 receptors), and in 
systems lacking CB1 and GABAB receptors (i.e., CB1- and GABAB-KO mice).  
Then, using the BRET approach we monitored dissociation between Gαo and Gβγ subunits 
and their conformational rearrangements before and after GABAB receptor activation. In 
addition, we studied the molecular interaction between the D2 receptor and Gαi1 protein 
subunits (Gαi1-60, Gαi1-91 and Gαi1-121), and using the same assay we detected the 
conformational changes between the Gαi1 and Gβγ subunits.  Next, we evaluated the effects of 
SR on adenylate cyclase activity, using BRET with the CAMYEL sensor, a recent technique 
developed to detect the level of cAMP in living cells. Specifically, the inhibitory effect of SR 
on Gi and Gs protein pathways measuring the BRET signal in cells transfected with 
CAMYEL and GABAB, D2 or D1 receptors was investigated. Finally, whole cell voltage 
clamp recordings from midbrain dopamine neurons in acute rat brain slices ex vivo were 
performed to evaluate the effects of SR on baclofen and quinpirole-induced outward K+ 
current both in wild type (WT) and CB1-KO mice. In addition, in order to demonstrate that 
SR induced the inhibition of GIRK channel activity by acting directly on G protein, we used a 
GPCR-free experimental setup  (i.e. whole cell patch clamp experiments were performed in 
CHO cells transfected with GIRK1/2). The main finding of this study is that SR, at 
micromolar concentrations, prevents GPCR-G protein signaling through a direct interaction 
with the G proteins mainly with the subunits αi/o.  
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In the first Chapter, a brief introduction to the GPCRs, G proteins and their downstream 
signaling components will be firstly presented (paragraph 1). In the second paragraph of the 
first chapter, the Endocannabinoid System, its components such as endogenous ligands, the 
cannabinoid receptors and their ligands will be briefly presented. In order to introduce the 
main object of this thesis and better clarify the rationale of this project, the third paragraph of 
the same chapter will describe Rimonabant/SR, with a brief excursus of its previously 
reported effects in in vitro and in vivo.  
In the second Chapter, the materials and methods employed to carry out this project will be 
described. In the third Chapter, a summary of results obtained through the in vitro [35S]GTPγS 
binding assay, BRET and electrophysiological techniques will be reported. Finally, in the 
fourth Chapter, a detailed discussion of our results will be offered to connect them to the 
literature and provide some final remarks on the meanings and implications of this study.  
 
 
 
 
 
 
 
 
 
Chapter 1. Introduction 4 
Chapter 1. Introduction 
1.1 G protein-coupled receptors 
Communication between cells is one of the principal characteristics of the multicellular 
organism. This process is due to the existence of transmitters released from a cell, and that 
triggers the response after specific recognition by specialized proteins. Numerous receptors on 
the cell surface have been identified so far, and it is possible to classify them in three different 
groups.  
The first group, the ionotropic receptor, is formed by ion channels, which control the 
permeability and the fast response of the cell, through altered ionic fluxes. 
The second group, the ligand-gated receptor, is represented by ligand-activated membrane-
bound tyrosine kinases that mediate cell proliferation and differentiation. 
The third group gathers the G-protein-coupled receptors (GPCRs) that regulate intracellular 
responses involving Guanine-nucleotide-binding proteins (G-protein) and multiple 
membrane-bound and intracellular partners. GPCRs represent the largest and most diverse 
group of plasma membrane receptors essential to normal physiology and are involved in 
critical functions such as vision, metabolism, olfactory perception, the endocrine system, 
neuromuscular regulation and central nervous system (CNS) functioning. 
There are more than 800 GPCRs identified in the human genome, most of them showing to 
have a relevant function on various diseases, including metabolic, neurodegenerative and 
psychiatric disorders and cancer. GPCRs are today the targets of 40% of all drugs on the 
pharmaceutical market, a percentage that is increasing over time.  
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1.1.1 Structure and classification  
GPCRs consist of a single peptide containing seven hydrophobic trans-membrane (TM) 
regions (TM-I through VII), known as α-helices, which cross the plasma membrane, and are 
connected by three hydrophilic intracellular domains (IC1, IC2 and IC3) and three hydrophilic 
extracellular loops (E1, E2 and E3). Two cysteine residues on E1 and E2 form a disulphide 
bond, which is probably important for the packing and for the stabilization of a restricted 
number of conformations of the seven TM regions. The N-terminal is exposed to the 
extracellular environment while the C-terminal is intracellular (Fig. 1). Generally, the ligand 
recognition site involves the extracellular domains of the receptor and the pocket formed by 
the assembly of the seven-TM helices. Indeed, the intracellular interaction involves the C-
terminal and intracellular loops with signal partners. The conformation change of the core 
domain generally includes the IC2 and the IC3, which are directly linked to TM-III and TM-
VI (Wess J., 1998). This mechanism constitutes one of the key sites for G-protein recognition 
and activation. Although the structure remains similar among distinct GPCRs, they differ in 
the length and function of their N-terminal, C-terminal domains and intracellular loops. 
Sequence homologies are restricted to the transmembrane domains of closely related 
subtypes. Moreover, some aspects of molecular interaction are conserved throughout the 
superfamily, but details may be different, in particular: 1) the extracellular portion of the 
receptor that interacts with ligands; 2) the intracellular portion that interacts with the cytosolic 
proteins and 3) the portion involved in the plane of the lipid bilayer. For this reason, 
mammalian GPCRs are classified in three different families (Fig. 2). 
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Figure 1. GPCR illustration: The central common core consisting of seven transmembrane (TM) helices (TM-I 
to TM VII) connected by three intracellular (IC1, IC2 and IC3) and three extracellular (E1, E2 and E3) loops. 
 
 
Family 1 represents the largest group, known as the Rhodopsin-like receptor family, and 
includes receptors for hormones, neurotransmitters, and light receptors; all of them transduce 
extracellular signals through interaction with G-proteins. Some ligands typically bind to the 
outside surface of the plasma membrane; others can dip into the helical bundle. Three regions 
of these receptors have been postulated to play a critical role in the conformational change of 
these receptors: the bottom of the major intrahelical ligand-pocket, the connection between 
helix 8 and the cytosolic surface of the lipid bilayer, and the cytosolic face, that might interact 
with the G protein. 
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Family 2 contains receptors for hormones and peptides, e.g. calcitonin, glucagon, secretin and 
diuretic hormone. This family has a characteristic long N-terminal tail containing six 
conserved cysteine residues with three disulphide bonds that contribute to form a hydrophobic 
binding cleft for the peptide ligands. The change of the amino terminus orientation is critical 
for biological activation (Grace et al., 2004).  
Family 3 is characterized by a very large N-terminal domain, with a Venus flytrap-like 
structure that plays an important role in ligand binding (White et al., 1998). The Venus flytrap 
domain is formed by a central β-sheet supported on both sides of the α-helices, connected by a 
hinge region to a central cleft. This domain is situated above a cysteine-rich domain that 
contains four intra-domain bonds; one of them directly links to the Venus Flytrap domain. 
The disulphide bonds seem to be critical for function, and increase the degree of rigidity of 
the receptor structure. Dimerization is a fundamental phenomenon of these receptors. The 
homodimeric structures are established by both covalent and no-covalent interactions; one 
large protein ligand can cross both protomers of the dimeric N-terminal structure. There are 
22 GPCR subtypes for this family that are divided into four groups depending on the ligands: 
1) metabotropic glutamate receptors, 2) calcium-sensing receptors and GPCRC6A, 3) GABAB 
receptors, and 4) orphan receptors (Miller et al., 2010). 
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Figure 2. GPCRs classification. Three main families of GPCRs, namely Family 1 (a), Family 2 (b) and Family 
3 (c), have been classified by comparing their amino-acid sequences (Clare Ellis, The state of GPCR research, 
The Nature Reviews Drug Discovery, 2004). 
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In summary, the structure of all these receptors is made up of seven TM helical segments that 
are arranged in a bundle in the lipid bilayer; and coupling with heterotrimeric G protein can 
induce biological effects. The interaction with different ligands requires the presence of a 
“ligand binding pocket” that is represented by the orthosteric natural binding pocket or the 
allosteric binding pocket. There are different features in these ligand-binding pockets for 
different GPCRs. Typically about 50-60% of residues are identical between family subtypes 
binding to the same ligands. Another important feature revealed by analysis of multiple 
crystal structures is the relative rigidity of the binding pockets (Katritch et al., 2012).  
In contrast to the variety observed in the extracellular domains, multiple crystal analyses 
revealed high structural conservation in the IC parts. These regions are involved both in the 
binding to G protein and arrestin, and in downstream signal transductions through 
mechanisms that are supposed to be similar among GPCRs. IC domains undergo large 
conformational changes after receptor activation (Milligan and Kosteins, 2006). In particular, 
the IC3 domain displays a high variable length and sequence among GPCR families, and is 
believed to control receptor selectivity for different G proteins. These domains are therefore 
considered a potential alternative target for allosteric drugs (Katritch et al., 2012). 
Allosteric sites have been identified in many GPCRs, and found to be located in direct 
proximity to the ligand binding-pocket, in the seven TM helical bundle for Family 2 and 3, or 
in the IC part of the receptor for Family 1 (May et al., 2007). Further structural analysis is 
needed to understand the structure and dynamics of the complexity regions implicated in the 
conformation and activation of receptors leading to specific selectivity for downstream 
effectors. GPCR function involves specific interactions with numerous binding partners.  
 
 
Chapter 1. Introduction 10 
1.1.2 G proteins 
The complexity and specificity of GPCR signaling is due to the existence of the numerous 
closely related molecular species of their subunits. G proteins are specialized proteins that 
bind to the guanosine triphosphate (GTP) and guanosine diphosphate (GDP) nucleotides. 
Some G proteins, such as the signal proteins RAS, are small with a single subunit, while the G 
proteins associated with GPCRs are heterotrimeric. They consist of a α subunit and a βγ 
subunit complex. So far, 23 α subunits derived from 17 different genes have been identified 
and classified in four families and 6 β and 12 γ subunits have been described.    
The α subunit contains the guanine nucleotide binding site with intrinsic GTPase activity, and 
a helical domain that covers the GTP in on the core of the protein. The helical domain plays a 
key role in directing receptor binding specificity and effector activation, this domain is also 
the most divergent among the Gα subunits. Analyses of the crystal structure of G protein 
reveal the presence of three flexible regions, (switches I, II and III) which change the 
conformation in GTP-bound activation, becoming more rigid. The N-terminal domain is 
arranged due to its interaction with the β-propeller domain of β subunits (Wall et al., 1995), 
playing a relevant role in the activation process through direct specific protein-protein 
interactions. There are different residues that are critical mediators of receptor-G protein 
selectivity: α2-helix, α2-β4 loop region, α4-helix and α4-β6 loop domain. This selectivity is 
mediated by the Gα subunit but seems to be affected also by a network of specific contacts 
between the G protein and the receptor.  
The C-terminal of the Gα subunit was found to have an important role in the receptor-G 
protein interaction: for example, the adenosine diphosphate ribosylation in the last four 
residues by pertussis toxin leads to uncouple Gi/Go proteins from the receptor (Van Dop et al., 
1984). In addition, antibodies that can recognise C-terminal domains of the Gα subunit block 
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receptor-G protein signaling. The C-terminal domain possesses identical, or almost identical, 
residues between Gα subunits, but still exhibits differential coupling to receptors. Recently, 
numerous X-ray crystal structures revealed that the C-terminal binds to TM5 and to TM6 or 
IC3 of a GPCR (Mnpotra et al., 2014). 
Gα subunits are classified into: Gαs, with four different variants that derive from a single gene 
via alternative splicing of exon 3 (Milligan 2006); Gαi, pertussis toxin-sensitive G proteins 
known as Gαi1, Gαi2 and Gαi3, produced from different genes; and the Gαo gene that can be 
differentially spliced to generate Gαo1 and Gαo2 (Milligan et al., 2006). 
Gβ and Gγ subunits together form a close heterodimer. The Gβ subunit possesses a N-
terminal α-helix and a β-propeller fold formed by seven segments with a 40 amino acid 
sequence (WD-40 repeat).  
Gγ is formed by two α-helices linked with a loop and its N-terminal participates in a coiled-
coil interaction with the N-terminal α-helix of the Gβ subunit (Kimple et al., 2011). 
Many studies showed that lipid modification increases membrane localization of the Gβγ 
heretodimer that is relevant for receptor coupling. The dimer between the Gα GDP-bound 
subunit and the Gβγ subunit is formed via two principal interactions: 1) a β3/α-loop and the 
switch II of the Gα subunit within six out of the seven WD repeats of Gβ, and 2) a contact 
between the side of the β-propeller of Gβ and the N-terminal helix of the Gα subunit (Kimple, 
2011). These interactions play a key role in the competition between the Gβγ-subunit and Gα-
GDP and for βγ effectors. 
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Table 1. G protein subunits and their effector systems (Adapted from Hermans, 2003).  
 
 
Originally, it was thought that only Gα subunits interact with effectors, enzymes or ion 
channels, but it is clear now that the Gβγ subunit regulates effector affinity as well. 
The first identified G protein effector is the adenylate cyclase (AD) enzyme that catalyses the 
conversion of adenosine triphosphate (ATP) into the intracellular second messenger cyclic-
adenosine 3’,5’-monophosphate (cAMP). Thus, cAMP regulates the activity of the cAMP-
dependent protein kinase (PKA), and cAMP-regulated guanine nucleotide exchange factors 
(Epac 1 and Epac 2). 
This G-protein-mediated regulation of cAMP production represents one of the most relevant 
signal pathways able to alter cellular functions. 
There are 10 different isoforms of the AD, all of them stimulated by Gαs, and some are also 
regulated via the Gβγ subunit or via Ca2+-calmodulin, but always in the presence of the active 
Subunit Family Main subtypes Primary effector 
α αs 
αi/o 
 
 
 
αq/11 
 
α12 
Gαs, Gαolf 
Gαi-1, Gαi-2, Gαi-3 
GαoA, GαoB 
Gαt1, Gαt2 
Gαz 
Gαq, Gα11, Gα14 
Gα15, Gα16 
Gα12, Gα13 
Adenylate cyclase ↑ 
Adenylate cyclase ↓ 
K
+
 channels ↑ 
Ca
2+
 channels ↓ 
Cyclic GMP 
Phosphodiesterase ↑ 
Phospholipase C ↑ 
β 
 
 
 
 
 
 
γ 
β1-5 
 
 
 
 
 
 
γ1-11 
Different assemblies of 
β- and γ-subunit 
Adenylate cyclase ↑/↓ 
K
+
, Ca
2+
, Na
+
 channels  
Phospholipase ↑ 
Protein kinase C ↑ 
Protein kinase D ↑ 
Phosphatidylinositol  
3-kinase ↑ 
GPCR kinases ↑ 
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Gαs subunit (Luttrell, 2008). The activity of AD is inhibited by the Gαi protein, and modulated 
through phosphorylation by PKA and protein kinase C (PKC).  
Another effector partner of G protein is phospholipase C (PLC) that catalyses hydrolysis of 
the phosphatidylinositol membrane, producing two intracellular second messengers: inositol 
1,4,5-trisphosphate and diacylglycerol. The first regulates the Ca
2+
 efflux from the 
endoplasmatic reticulum, while the latter controls the activity of some isoforms of PKC. 
Gαi12 and Gαi13 proteins regulate cytoskeletal conformation and affect cellular growth by 
activating Rho family small GTPases proteins (Luttrell, 2008). These particular Gα subunits 
also bind to a Regulator of G Protein signaling (RGS), thereby stimulating its guanine 
nucleotide exchange factor (GEF) activity. The Gβγ subunit is found to regulate the G 
protein-coupled receptor kinase, GRK2 and GRK3, which play a key role in receptor 
desensitization.  
The Gαo subunit inhibits, with direct interaction, the high voltage N-type Ca
2+
 channel, 
whereas the Gαs subunit stimulates the L-type Ca
2+
 channel (Luttrell, 2008). 
It is now well established that the subunit Gβγ inhibits some voltage-activated Ca2+ channels 
and activates the G-protein-activated rectifying K
+
 channels (GIRKs or Kir3). These regulate 
the postsynaptic inhibitory effect of Gαi/o-inactivating transmitters in neurons. This family 
includes four subunits, GIRK1-4: GIRK 2 or GIRK 4 homotetramery, as well as GIRK1/2, 
GIRK1/3, GRIK 2/3 or GIRK1/4 heterotetramery that are essential to functionality (Dascal, 
2011). These subunits combine to form a classic K
+
 pore-forming transmembrane domain 
(M1 and M2) and a large cytoplasmatic domain (N-terminal and C-terminal). The re-entrant 
helix, named P-loop, forms the selectivity filter (Fig. 3). 
The Gβγ subunit binds to two or three separate segments in each GIRK subunit. This binding 
likely changes the conformation of the M2 segment and the proximal part of the C-terminal 
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that mediates open-close transition, allowing long-lasting periods of channel activity. This 
effect also alters the permeation and the gating on the selectivity filter (Dascal, 2001).    
 
 
 
Figure 3. Representation of a GIRK channel. (a) The channel core is a transmembrane and contains two 
domains (M1 and M2) and a helix-P-loop that forms the selective filter. (b) Channel structure viewed from 
above, the four subunits surrounding the central pore (Dascal, 2001). 
 
 
In contrast to the simple paradigm that a single receptor interacts with a particular G protein, 
or with multiple G proteins belonging to the same family, it is now accepted that many 
GPCRs can simultaneously couple distinct unrelated G proteins, leading to another 
mechanism for activation of multiple intracellular effectors by a single receptor (Hermans, 
2003). 
Several studies have shown that G protein subunit expression is controlled dynamically and 
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that GPCR activity could play a role in this regulation. Receptor-mediated selective regulation 
of the G protein could contribute to increase specificity of signal transduction between 
receptors that share a multiplicity of G proteins.  
Moreover, there are varieties of intracellular proteins that can control the activity of different 
partners of the G protein signal cascade. The family of RGS, for example, is able to increase 
the GTPase activity of Gα subunits, showing specificity for either Gq/11 or Gs protein types. 
 
1.1.3 Mechanism of signal transduction 
The conformational change from the inactive to the active state of a receptor is necessary for 
G protein activation. The mechanism of GPCR activation involves the disruption of 
intramolecular relation and the formation of new interactions. Specific movements of TM 
helices are essential for G protein activation. For example, the introduction of a disulphide 
cross-linking into TM3 and TM6 blocks G protein activation via cytoplasmatic loops. The 
magnitude of movement of TM6 is higher than those of TM3 and TM7, resulting in a greater 
exposition of the inner face of TM2, TM3, TM6 and TM7 (Karnik et al., 2003).  
There is some evidence to suggest specificity in receptor-mediated conformational changes 
with the G proteins. Perhaps, the most apparent connection is the α5-helix that links to the C-
terminal of the Gα subunit to the nucleotide binding pocket at the β6/α5 loop; mutations in 
this region are found to have effects on nucleotide exchange and to modulate receptor 
coupling (Oldham and Hamm, 2008). 
Using different techniques, it was found that a receptor induces perturbation in the α5 helix of 
G protein and this might be transmitted to the nucleotide-binding pocket via α1-helix and β2 
and β3 strands.  
The loop that connects the β6 strand and the α5-helix contains the guanine-ring-binding motif: 
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mutations in this residue enhance spontaneous GDP release  (Oldham and Hamm, 2008). 
Moreover the α3-β5 loop was reported to be important for interaction between the receptor 
and the Gαs subunits, while the N-terminal of both Gαo and Gαi subunits might have a role for 
GDP affinity interacting with β2 and β3 strands. Switches I, II and the phosphate-binding loop 
have an important interaction with GDP. 
G protein is considered in its “off state” when it binds to GDP and when the Gαβγ subunits 
form a heterotrimer, and in its “on state” when it binds to GTP. Receptor activation induces 
conformational change in the G protein, leading to GDP releasing from the Gαβγ heterotrimer 
(Fig. 4).   
Two models have been suggested to explain how the receptor induces conformational changes 
on Gαβγ subunits allowing GDP release. The first model, proposes that by using the N-
terminal of the Gα subunit as a lever arm, the receptor pulls the Gβγ dimer away from the Gα 
subunit. GDP release occurs when Switches I and II are preyed away from the nucleotide 
binding pocket.  
In the second model, it is proposed that the receptor uses the N-terminal of the Gα subunit to 
force the Gβγ dimer into the Gα subunit, leading the Gγ subunit to bind to the Gα-helical 
domain. GDP release might occur when this interaction causes a gap between the helical and 
the GTPase domain of the Gα subunit. 
This step is rate-limiting in G protein activation, and consequently it allows the activation of 
downstream signaling effectors. Since there is direct evidence of specific receptor-mediated 
conformational changes in G proteins, previous studies have found that interdomain 
interactions cause nucleotide exchange, although this also depends on Gα subunit 
involvement. For example, in Gαs and Gαi1 subunits these interactions can be disrupted 
leading to an increase in the rate of basal activity or a decreased rate of receptor-catalysed 
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exchange (Warner et al., 1998). The increased rate on basal exchange might lead to the 
opening of the interdomain fissure, which reduces GDP affinity. A reduced rate of catalysed 
exchange may explain how the receptor transmits a conformational change across the domain 
interface. Crystallography studies have revealed a movement of the GTPase domain and the 
helical regions relative to each other in order to release GDP (Ceruso et al., 2004). 
The displacement of GDP is followed by the binding of GTP that is more abundant in the 
cells, and causes a strong rearrangement in the Switch regions, leading to dissociation of Gα-
GTP and the Gβγ dimer. In this way, both complexes can interact and regulate effector 
systems. The Gα subunit has an intrinsic GTPase activity, and hydrolyses the terminal 
phosphate of GTP to restore GDP on the nucleotide-binding pocket. This binding allows the 
reassociation of the Gαβγ hetorotrimer and to the arrest of the cycle (Milligan and Kosteins, 
2006). 
 
 
Figure 4. The G protein cycle. Conversion of a G protein heterotrimer from a GDP-bound to a GTP-bound 
state, promoted by interaction with the receptor. 
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1.1.4 Properties of GPCR heteromers 
Constitutive activity is the ability of a GPCR to adopt an active conformation in the absence 
of an agonist. In 1982 and 1984 Koski and Cerione provided the first evidence for constitutive 
activity for the δ opioid receptor and β2-adrenoceptor. So far, more than 40% of all GPCRs 
have been found to exhibit constitutive activity (Seifert and Wenzel, 2002). 
To better understand this concept, the two-state model was proposed, assuming that GPCR 
exists in equilibrium between an inactive (R) state and an active (R*) state. In the R state, the 
receptor is uncoupled from G protein, whereas in the R* state, it can couple and activate G 
protein. As previously described, modifications of TM3 and TM6 lead to a conformational 
switch from R to R*. This particular mechanism is highly conserved among GPCRs 
(Bockaert and Pin, 1999). Importantly, the transition from R to R* can occur spontaneously, 
and independently from an agonist. 
This constitutive activity increases G protein basal activity and the activation of effector 
systems, in comparison with the absence of GPCR. Full agonists maximally stabilize the R* 
state and shift the equilibrium towards R*. Accordingly, agonists efficiently increase the basal 
GDP/GTP exchange rate of G proteins and increase effector system activity. Partial agonists 
are less efficient than full agonists at stabilising the R* state leading to a less efficient 
GDP/GTP exchange compared with full agonists. 
In contrast to full agonists, full inverse agonists maximally stabilize the R state and reduce 
basal GDP/GTP exchange, thereby blocking the effects of agonists. For this reason, several 
inverse agonists were originally classified as antagonists. 
On the contrary, a neutral antagonist, does not alter the equilibrium between R and R* and 
does not change basal G protein activity, yet blocks both the inhibitory effects of inverse 
agonists and the stimulatory effects of agonists (Wenzel and Seifert, 2002). 
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Moreover, the equilibrium position between R and R* is different for several receptors which 
might explain the various levels of basal activity for different GPCRs.  
The classical view of receptor activation was overtaken by the discovery of the ternary 
complex model. This model proposes that the receptor interacts with its cognate G protein 
independently from the presence of the ligand, and that an active receptor complex can be 
formed only when all three components are associated, forming the ternary complex AR*G. 
However, this model limited the existence of the receptor in its inactive state (agonist free) 
and active state (agonist bound). The extended ternary complex model provided a mechanism 
that considers the spontaneous formation of an active-state receptor independently from the 
presence of the agonist, and the possibility that the receptor binds to the G protein in its active 
state (R*G) or inactive state (RG), leading to alterations in the affinity between receptor and 
G protein (Fig. 5).  
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Figure 5. Evolution of the ternary complex.  (A) Receptor ligand interaction model with the G protein bound 
to the activated receptor. (B) Evolved model to explain ligand independent G protein activation. A: agonist, R: 
inactivated receptor, R*: activated receptor, G: G protein (Greasley and Clapham, 2006). 
 
 
Several studies suggest that the interaction between the receptor and the G protein occurs 
before the activation process. An alternative hypothesis proposes that G protein might pre-
assemble with the inactive receptor. Previously, studies have found that the β2-receptor can be 
associated with Gαs subunits or Gβγ independently from its activation suggesting the 
existence of a preassembled signaling complex (Duc et al., 2015). 
Bouaboula et al. (1997) have demonstrated that a cannabinoid receptor inverse agonist could 
block the constitutive activity of the receptor by sequestering the Gα subunit in its GDP-
bound form, blocking Cannabinoid receptor type 1 (CB1) signaling a downstream cascade.   
The ability of ligands to decrease or increase the separation of G protein subunits, which 
induce an inhibition or activation of cellular effectors, is one representation of ligand efficacy 
(Kenakin, 2002).  
In this context, it is important to evaluate whether there are therapeutic differences in the 
clinical use of drugs having negative efficacy versus neutral blockers. Indeed, the basal 
activity of GPCRs plays a role in the physiological system and molecules that have negative 
efficacy might be used for many conditions.   
Classically, the drug discovery process selects and optimizes compounds that interact 
selectively with a specific receptor, but previous studies have shown that critical conditions, 
such as cancer or pain, are to ascribe to the concomitant activation of many different GPCRs. 
For this reason, understanding the mechanism underlying the negative efficacy of drugs on 
basal activity, may lead to novel therapeutic strategies, since the simultaneous blockade of the 
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various GPCRs involved could be relevant in these pathologies.  
During the process of activation and deactivation, G protein subunits interact with different 
reaction partners: the binding sites of these interactions could be considered as relevant targets 
for synthetic ligands. 
Over the last two decades, new theories have been developed to explain how a ligand can 
induce or stabilize different receptor conformations, resulting in activation of distinct 
effectors (Fig. 6). Heteromerization, i.e. association of different GPCR types, today represents 
a potential new mechanism that can explain the different regulation of GPCR signaling and 
their specificity (Rozenfeld and Devi, 2011). 
Many studies have reported that the heteromerization of receptors alters G protein activity and 
interaction. For example, association between the μ opioid receptor (MOR) and the δ opioid 
receptor (DOR) decreases MOR activity in response to an agonist (Gomes et al., 2000), while 
association with the CB1 receptor does not affect its activity (Rios et al., 2006). Other 
evidence indicates that heteromerization can cause a switch in G protein coupling. Despite 
MOR and DOR coupling to the Gαi subunit when they are expressed individually, their 
heteromerization changes the coupling from Gαi to Gαz (Hasbi et al., 2007). Previously, 
studies on D1 and D2 receptors have shown that heteromerization between these two 
receptors leads to a switch from Gαs/olf (for D1) and Gαi (for D2) to a Gαq/11 (So et al., 2007).  
Together, these findings suggest the possibility that heteromerization might influence 
diversification of receptor properties, which could contribute to the regulation of receptor 
function in vivo (Rozenfeld and Devi, 2011). 
Lastly, mutations that cause constitutive activation of G protein α subunits have been found in 
different human diseases. Most of these mutations alter the G protein coupling efficiency or 
induce agonist-independent signaling activity. The possible influence of these mutations on 
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the interaction with different G proteins remains to be explored (Hermans, 2003).  
 
 
Figure 6. Functional interactions of GPCRs. Activation of two different GPCRs induces two independent 
signaling pathways A and B, resulting in two independent effects, 1 and 2. Interaction of GPCRs results in the 
activation of the heteromer-specific signaling pathway C responsible for   downstream effect 3. 
 
 
1.1.5 The role of GPCRs in the pathophysiology of human diseases 
GPCRs play an important role in modulating tissue and cell physiology and homeostasis and 
their signal pathways are associated with various pathological processes such as neuronal 
degeneration, cancer, cardiovascular and immune system disease.  
Moreover, GPCRs are potential targets for treating several pathophysiological disorders 
including obesity and metabolic syndromes. These pathological conditions are extremely 
complex and multifactorial, but there is evidence that neuropeptides binding to GPCRs can 
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regulate appetite and have effects on its pathophysiology. In addition neuropeptides regulate 
energy homeostasis through feeding behaviour and food intake, representing a promising 
target for treating obesity (Kimple et al., 2011). 
Several members of GPCRs are found to have roles in pancreatic function and glucose 
homeostasis and in type-2 diabetes (Kimple et al., 2011). 
The pathophysiology of heart diseases is characterized by the chronic activation of different 
GPCR signaling systems. So far, only a small fraction of these receptors, such as the 
angiotensin, endothelin, adrenergic and adenosine receptors have been characterized as 
potential drug targets for cardiac therapy (Heng, 2013).  
Different functions of GPCRs have been evaluated in the pathophysiology of cancer and 
today they are being investigated as potential drug treatment targets, due to their involvement 
in the uncontrolled growth and proliferation of cancerous cells, metastasis, angiogenesis, 
differentiation pathways and alteration of the normal apoptotic pathway, and cross-talk with 
other non-GPCRs (Heng, 2013). 
The physiology of some neurodegenerative diseases such as Alzheimer’s, Parkinson’s and 
Huntington’s, involves the main GPCRs expressed on CNS. First of all, muscarinic 
acetylcholine receptors (M1 and M3), metabotropic glutamate receptors (mGlu1-4) and 
serotonin (5-HT) receptors are implicated in the formation of amyloid plaques through the 
modulation of α-,β-,γ-secretase involved in the neurodegeneration of Alzheimer’s disease. 
The major groups of GPCRs’ target for Parkinson’s disease are the dopaminergic receptors 
and metabotropic glutamate receptors. The selective loss of dopaminergic neurons suggest 
that dopamine receptor stimulation might provide some symptomatic relief for this disease as 
well as the stimulation of mGlu-4 signaling that enhances neurotransmission in the basal 
ganglia (Kim et al., 2010). 
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Dyskinesic symptoms are due to an imbalance between striatal dopaminergic and cholinergic 
activity. For this reason, another strategy may be to inhibit muscarinic acetylcholine receptor 
signaling as an alternative therapy. Parkinson disease is also characterized by loss of 
serotoninergic activity, and therefore the 5-HT 1A, 1B, 2A and 2C subtypes are potentially 
promising drug targets.  
Glutamate receptors mediating excitotoxicity are the major players in the pathogenesis of 
Huntington’s disease. Also, the CB1 receptors represent a promising target. Depletion of 
Endocannabinoid signaling is another biomedical hallmark of this pathology and stimulation 
of CB1 receptors could have beneficial therapeutic effects (More and Choi, 2015). 
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1.2 The Endocannabinoid System 
The discovery, in 1990 and 1993, of a specific membrane receptor of marijuana’s 
psychoactive component, (-)-Δ9-tethrahydrocannabinol (THC), led to the discovery of an 
endogenous signaling system, known today as the “Endocannabinoid System” (ECS). 
In mammalian tissue there are two types of cannabinoid receptors: CB1, found predominantly 
in the central nervous system and less in the peripheral nerve terminals and cannabinoid 
receptor type 2 (CB2), localized primarily on immune cells (Howlett et al., 2004). Both CB1 
and CB2 receptors are coupled to the Gi/o subtype of G-proteins, and when activated by 
agonists they inhibit the activity of adenylyl cyclase, activate mitogen-activated protein 
(MAPK) kinase and inhibit the function of voltage gated Ca
2+
 channels. Only CB1 receptors 
have been found to modulate the activity of K
+
 channels (Katona and Freud, 2012). 
The ECS consists of endogenous ligands, named endocannabinoids (EC) that target the CB1 
and CB2 receptors, and of enzymes and processes responsible for their biosynthesis, 
metabolism, cellular uptake and inactivation (Katona and Freund, 2012). 
The EC, present in the brain and peripheral tissues, are derivatives (amides, esters and ethers) 
of a long-chain polyunsaturated fatty acid, mainly arachidonic acid, capable of binding and 
functionally activating the cannabinoid receptors (Di Marzo et al., 2004). To date, several EC 
have been identified, see Fig. 7 (Pertwee,  2015). 
The most studied EC so far are anandamide (N-arachinodil-ethanolamine, AEA), 2-
arachinoyl-glycerol (2-AG), 2-arachidonyl-glyceryl ether (noladin, 2-AGE), O-arachidonoyl-
ethanolamine (virhodamine) and N-arachidonoyl-dopamine (NADA) (Fig 7). 
Due to their hydrophobic structure, their main cell signaling actions are limited to paracrine 
(cell-to-cell) or autocrine (same cell) signaling, rather than systemic effects, mediating 
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retrograde signaling that may lead to the inhibition of neurotransmitter release (Svinzeska et 
al., 2008). 
They present unique characteristics since they: 
• present a lipid structure that makes them lipophilic  
• are hydrophobic with limited mobility in an aqueous environment  
• are deputed to local cell-signaling (paracrine or autocrine)  
• are formed from the internal lipid constituents of the cellular membrane  
• are synthesized and released “on demand” and not stored in resting cells  
• have a very short half-life  
• undergo degradation by Fatty Acid Amide Hydrolase (FAAH)  
 
 
 
Figure 7. Chemical structures of Endocannabinoids and Cannabinoids (Pertwee, 2015). 
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The activity of EC is controlled by their endogenous levels, and therefore by a balance 
between biosynthetic and degradative mechanisms. 
The level of 2-AG in no-stimulated tissues and cells is usually much higher than other EC and 
it acts on both cannabinoid receptors. 2-AG is at the crossroad of several metabolic pathways 
and is an important precursor of arachidonic acid and/or degradation product of arachidonic 
acid and of phopho-, di- and triglycerides. In previous studies several stimuli have been found 
to lead to the formation of 2-AG in neuronal and non-neuronal cells (Sugiura et al., 2002).  
It was postulated that EC are not stored in pre-formed vesicles, yet they are synthesized and 
released “on demand”. However, more recent views have imposed a reconsideration of this 
“dogma”, because AEA can be stored in adiposomes and is bound to intracellular transporters 
(Maccarrone et al., 2010). 
Once released into the extracellular space by a putative endocannabinoid transporter, EC are 
cleared away from their extracellular targets. This process is driven by controllable and 
selective mechanisms such as by the membrane transport protein or intracellular enzymatic 
process. Degradation by FAAH and monoacylglycerol lipase (MAGL) which cleave 
anandamide and 2-AG, respectively, into arachidonic acid and ethanolamine, and arachidonic 
acid and glycerol, leads to the diffusion of these compounds from the extracellular milieu into 
the extracellular space (Glaser et al., 2003). 
EC act primarily at CB1 and CB2 receptors, AEA, NADA and 2-AGE are more selective for 
CB1, while virodhamide seems to have more affinity for CB2 (Mukhopadhyay et al., 2002). 
It is now well established that AEA and 2-AG do not interact only with these receptors, they 
exhibit instead a degree of promiscuity that applies also to the less-studied arachidonic acid-
derived endocannabinoids (Di Marzo and De Petrocellis, 2012). 
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A receptor with a different distribution to CB1 receptors and sensitive to AEA has been 
discovered in several brain areas of CB1 knock out (KO) mice. This receptor, named 
Transient Receptor Potential Vanilloid 1 Receptor (TRPV1), has been described in vascular 
endothelial cells where it controls the local vasodilatation but not in systemic effects induced 
by AEA. Furthermore, some plasma membrane channels involved in Ca
2+
 and K
+
 homeostasis 
also appear to be targeted by micromolar concentrations of AEA (Di Marzo et al., 2002). 
The ECS regulates a variety of physiological processes and plays an important role in the 
control of mood, which makes it critical for the pathogenesis of several psychiatric disorders. 
The first psychoactive compound of Cannabis sativa, THC was identified and characterized 
in 1964. Since its discovery, additional active compounds have been identified, but THC is 
still one of the most widely used illicit drugs, since it promotes relaxation and euphoria. It 
influences the CNS in a complex manner, and its chronic use may promote dysphoria, 
depressive mood and increased anxiety. Numerous selective and non-selective agonists and 
antagonists of CB1 receptors have been developed and used as tools to elucidate the role of 
the ECS. Few of them have advanced to clinical trials for treatment of pain, obesity, 
neurodegenerative disorders, inflammation and nicotine and alcohol addiction.  
 
 
1.2.1 Cannabinoid receptors  
The characterization and distribution of CB1 receptors in the CNS plays a key role in 
understanding the pharmacological effects of specific agonists and antagonists of these 
receptors. 
CB1 and CB2 receptors belong to the superfamily of receptors that couple to G proteins, with 
seven hydrophobic transmembrane domains connected by extracellular and intracellular 
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loops, an N-terminal extracellular domain and a C-terminal domain which binds to the G 
protein complex (Bramblett et al., 1995). 
The CB1 receptor has been cloned from rat, mouse and human tissues and exhibits a 97-99% 
amino acid sequence identity across species. It is one of the most abundant GPCR in the CNS, 
but it has also recently been found in cardiovascular tissue, the reproductive system and in the 
gastrointestinal tract (Croci et al., 1998; Sazbo et al., 2001).  
 
 
        
 
Figure 8. Schematic representation of CB1 receptor distribution in the rat brain (Flores et al., Frontiers in 
Neuroscience, 2013).   
 
 
The CB1 receptor is coupled to Gi/o proteins to inhibit adenylyl cyclase, activate MAPK, 
inhibit voltage gated Ca
2+
 channels and activate inwardly rectifying K
+
 channels (Howlett et 
al., 2000; Pertwee, 1997). It was found mainly at the terminals of central and peripheral 
neurons, where they usually mediate inhibition of the release of a range of different excitatory 
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and inhibitory neurotransmitters (For a review see Howlett et al., 2002; Pertwee and Ross, 
2002; Szabo and Schlicker, 2005). 
CB1 receptors have also been found on postsynaptic structures and in some astrocytes, 
microglia (Rodriguez et al., 2001; Stella 2010; Bosier et al., 2013), and oligodendrocytes and 
these cells are also able to synthetize and degrade EC (Walter et al., 2002; Stella 2009). 
Lastly, a recent controversial study (Benard et al., 2012; Hebert-Chatelain et al., 2014; 
Morozov et al., 2013) reported that CB1 receptors are associated with mitochondria in 
astrocytes, where they may play a role in energy balance and synaptic plasticity.   
The CB1 receptor has a wide and characteristic distribution in the CNS: it is particularly 
enriched in the cortex, hippocampus, amygdala, basal ganglia outflow tracts, and cerebellum, 
this distribution being linked to the most prominent behavioral effects of cannabinoids 
(Mackie, 2005). 
As shown in Fig. 8, high density of CB1 receptors in the hippocampus is associated with 
disruptive effects of cannabinoids on memory and cognition (Herknham et al., 1990). High 
concentration on basal ganglia could be related to the role of EC in the fine-tuning of motor 
control. Previous studies have shown that CB1 receptor expression and binding is decreased 
in neurodegenerative diseases, such as Parkinson’s and Huntington’s (Glass et al., 1997).   
High density of CB1 receptors on the rat cerebellum may have a role in the immobility, 
catalepsy and ataxia observed after acute administration of THC and other cannabinoids in in 
vivo experiments (Fonseca et al., 1998). In contrast, a low density of CB1 receptors in the 
human cerebellum is linked to effects on motor function after THC use (Herknham et al., 
1990). 
Others brain regions present a moderate density of CB1 receptors, such as the medial 
hypothalamus, basal amygdala and solitary nucleus. 
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Stimulation of CB1 receptors on the hypothalamus interferes with the level and action of 
neuropeptides regulating energetic homeostasis, food intake, and lipogenesis in peripheral 
tissues and increases leptin release from the adipose tissue (Cota et al., 2003).     
Stimulation of CB1 receptors in the nucleus accumbens increases the dopaminergic reward 
pathway and influences the motivation to eat and to take drugs of abuse. (Parsons and Hurd, 
2015) 
A high density of CB1 receptor on the periaqueductal grey and dorsal horn of the spinal cord 
is related to their involvement in pain modulation (Maldonado et al., 2006). 
Stimulation of CB1 receptors by THC and other cannabinoid receptor agonists involves 
beneficial effects such as analgesia, attenuation of nausea and vomiting in cancer 
chemotherapy, reduction of intraocular pressure, appetite stimulation, relief from muscle 
spasm and spasticity in multiple sclerosis (Pertwee et al., 2000). Unfortunately, there are 
numerous side effects associated with these therapeutic effects, including alterations in 
cognition and memory, sedation, dysphoria/euphoria and panic (Howlett et al., 2002). 
The CB2 receptors have been found predominantly in peripheral cells and immune cells (i.e. 
leucocytes) spleen and tonsils. They have also been identified in the gastrointestinal system 
and in numerous other cell types, including pulmonary endothelial cells (Zoratti et al., 2003), 
adipocytes (Roche et al., 2006), osteocytes, osteoclasts and osteoblasts (Ofek et al., 2006). 
Indeed, it has been reported that 2-AG affects meiosis in spermatogonia via CB2 and a 
number of other aspects of reproductive function (Maccarrone, 2008; Grimaldi et al., 2009).  
CB2 receptors have also been found in the CNS, in both microglial and neuronal cells (Ameri, 
1999; Gong et al., 2006; Atwood and Mackie, 2010) and when activated can modulate 
immune cell migration and cytokines release within the brain. The neuronal presence of CB2 
receptors on neurons was a matter of debate for a long time, due to low levels of CB2 
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compared to CB1 receptors, the presence of CB2 in microglia and endothelial cells, and 
nonspecific antibodies. 
Indeed, recent considerable functional and anatomical evidence suggests that the CB2 
receptor is expressed in the CNS mainly in activated microglia and very likely in some 
neurons (Atwood and Mackie, 2010). 
In line with these notions, the CB2 receptor is implicated in the control of the proliferation, 
differentiation and survival of neuronal and non-neuronal cells. There are conflicting studies 
that show both apoptosis and inhibition of tumour growth in host cells after CB2 receptor 
stimulation (Romero et al., 2002; Guzman 2003). Recently, several studies have reported that 
this receptor is also involved in brain neuroinflammation and neurodegenerative diseases, 
including Alzheimer’s disease, Huntington’s chorea, amyotrophic lateral sclerosis and others. 
Interestingly, in experimental models of these disorders, the activation of CB2 receptors has 
been related to a delayed progression of neurodegenerative events, in particular, those related 
to the toxic influence of microglial cells on neuronal homeostasis (Fernandez-Ruiz et al., 
2008). 
 
1.2.2 Classification of Cannabinoid receptor ligands 
The discovery and characterization of CB1 and CB2 receptors were followed by the 
development of different molecules, which can be subdivided into two classes: agonists and 
antagonists/inverse agonists. 
Cannabinoid receptor agonists are classified according to their chemical structures into: 
1. “Classical” Cannabinoids: this group consists of ABC-tricyclic dibenzopyran 
derivatives that are either natural compounds obtained from Cannabis sativa, or 
synthetic analogs (Fig. 9). The most investigated of this group are Δ9-THC, Δ8-THC 
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and HU-210 (11-hydroxy-Δ8-THC-dimethy-pentyl), all inducing cannabimimetic 
responses in vivo and in vitro. 
 
Figure 9. Chemical structures of ABC-tricyclic dibenzopyran derivatives. 
 
 
2. “Non-classical” cannabinoids: during the course of studies of the structure-activity 
relationship to obtain an analgesic effect, researchers at Pfizer synthesized new 
analogues without the dihydropyran ring of THC (Fig. 10).  These compounds were 
CP47497 and its bicyclic derivative, CP55940 that is still the agonist most used for 
radioligand binding assays. It binds to CB1 and CB2 receptors with similar affinity 
and displays high affinity in vivo with more potency than Δ9-THC. 
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Figure 10. Chemical structures of “non-classical” cannabinoids. 
 
3. Aminoalkylindoles: this class results from the modification of a series of non-steroidal 
anti-inflammatory compounds. R-(+)-WIN55212 is the most commonly used and 
studied, and displays affinity for both CB1 and CB2 receptors, with moderate 
selectivity in the CB2 receptor. In vivo, it produces the same pharmacological effects 
of THC (Howlett et al., 2002). 
4. Eicosanoids: consist of prostaglandins (PG), thromboxanes (TX), leukotrienes (LT) 
and lipoxins (LX). They produce a wide range of biological effects on inflammatory 
responses, on the intensity and duration of pain and fever, and on reproductive 
function. They also play important roles in inhibiting gastric acid secretion, regulating 
blood pressure through vasodilation or constriction, and inhibiting or activating 
platelet aggregation and thrombosis. The principal eicosanoids of biological 
significance to humans are a group of molecules derived from the C20 fatty acid, 
arachidonic acid (Szefel et al., 2015). 
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CB1 receptor agonists in vivo assays show the so-called “mouse tetrad”, which reveals their 
ability to produce hypokinesia, hypothermia, catalepsy and antinociception. There are no 
standard in vivo bioassays for CB2 receptor agonists. Repeated administration of CB1 
receptor agonists can cause tolerance possibly due to receptor internalization and or to 
alterations in cAMP and PKA activity (Sim-Selley, 2003).   
In in vitro bioassays these agonists are commonly used to measure the effect on signal 
pathways that involve CB1 and CB2 receptor activation. For example, stimulation of binding 
to G proteins of the hydrolysis-resistant GTP analogue [
35
S]GTPγS decreases cyclic AMP 
production and has an effect on the intracellular concentration of Ca
2+
 and K
+
 (Pertwee 2006). 
 
The cannabinoid receptor antagonists/inverse agonists are classified as follows (see Fig. 11): 
1. Diarylpyrazoles: the prototypic compounds of this series are the Sanofi molecules 
SR1417161A (SR) and SR144528. Both prevent or reverse effects mediated by CB1 
and CB2 receptors, respectively. However, there are many studies that showed the 
ability of SR141716A to produce opposite effects as compared to those produced by 
cannabinoid agonists. They can behave as inverse agonists and reduce the constitutive 
activity of signal transduction pathways (Howlett et al., 2002). Two analogues of SR, 
AM251 and AM281 have been found to produce inverse cannabinoid mimetic effects 
in CB1 receptor bioassay systems. AM251 suppressed rat food intake and food-
reinforced behavior, it inhibited the basal G protein activity in rat cerebellar 
membranes and it enhanced the electrically-evoked glutamate release from rat 
cerebellar neurons (Pertwee et al., 2005). AM281 increased mouse locomotor activity, 
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and it inhibited the basal [
35S]GTPγS binding to primary cultures of rat cerebellar 
granule cells (Pertwee et al., 2005). 
 
 
 
Figure 11. Chemical structures of cannabinoid receptor antagonist/inverse agonists. 
 
 
2. Other compounds: the most used of the benzofuran series is LY320135, developed by 
Eli Lilly, found to have much higher affinity for the CB1 receptor than CB2 receptors, 
the AM630 is selective for CB2 (Howlett et al., 2002). 
 
All the aforementioned diarylpyrazoles produce inverse cannabinoid mimetic effects in at 
least one bioassay system. For example, the in vivo inverse effects of these compounds in rats 
or mice include hyperalgesia in models of inflammatory and neuropathic pain, the stimulation 
of intestinal motility and food intake (Pertwee et al., 2005). 
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In vitro, the inverse agonist effects include increase in acetylcholine, noradrenaline and 
aminobutyric acid release in hippocampal slices, and inhibition of [
35S]GTPγS binding in 
membrane preparations (Pertwee et al., 2005). 
Cannabinoid receptor ligands as well as agents that might modify cannabinoid transport, 
metabolism and activity of the ECS might be used as potential hypnotics, analgesics, 
antiemetic, antihypertensive and immunomodulatory drugs, anti-inflammatory, antiepileptic 
and drugs, but also for treating glaucoma, spasticity, eating disorders and alcohol withdrawal 
(Svíženská et al., 2008).  
There is evidence that not all inverse cannabinoid mimetic effects are produced through a 
single mechanism. This project is aimed to understand the mechanism of the inverse agonist 
of SR.  
 
1.2.3 CB1 receptor cross-talk with other endogenous systems 
The broad distribution of CB1 receptors in the CNS underlines their modulatory role in 
several neurotransmitter systems. 
Metabotropic GABAB and CB1 receptors have been found to display similar pharmacological 
effects and localization in different brain regions. The GABAB receptor belongs to Family C 
of the GPCRs and its distribution reflects its pharmacological relevance. At a presynaptic 
level it is present on inhibitory and excitatory terminals where it suppresses neurotransmitter 
release by inhibiting the voltage-sensitive Ca
2+
-channel and by modulating synaptic vesicles. 
At a postsynaptic level, GABAB receptors induce a slow inhibition through activation of K
+
 
channels, which hyperpolarizes the membrane and avoids the current propagation (Bettler and 
Tiao, 2006). 
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By regulating neurotransmission, GABAB receptors are an important therapeutic target in the 
treatment of psychiatric disorders, epilepsy, drug addiction and pain (Pinard et al., 2010). 
Both CB1 and GABAB receptors play a relevant role in pathways involved in cognition, 
learning, memory and anxiety. Previous studies reported functional interaction between CB1 
and GABAB receptors. In the cerebellum both receptors are localized on granule cells and 
share a common adenylyl cyclase catalytic unit (Cinar et al., 2008). In contrast, in the rat 
hippocampal synapses they are coupled to Gαo1, Gαi2 and Gαi3 but not Gαi1. One possible 
explanation for the cross-talk between CB1 and GABAB receptors is the competition for a G 
protein common pool. Recently, it was found that CB1 receptors can sequester Gi/o proteins 
and prevent α2-adrenergic and somatostatin receptor signaling. It was also demonstrated that 
sequestration is specific to the pertussis toxin-sensitive Gi/o proteins (Vàsquez and Lewis, 
1999).  
The ECS is involved in memory, learning and reward and overlaps with the dopaminergic 
system. There is evidence of a functional interaction between these two systems, in particular 
between D2 and CB1 receptors. D2 receptors belong to GPCR Family 1 and are involved in 
numerous signal transduction pathways, such as the inhibition of adenylate cyclase activity, 
inwardly rectifying K
+
 and Ca
2+
 channels, and mitogen-activated protein kinases (Vanhauwe 
et al., 1999). With in situ hybridization assays and immunocytochemistry techniques the co-
localization of the CB1 and D2 receptor in rat caudate putamen and nucleus accumbens was 
demonstrated. Moreover, CB1/D2 co-expression has been found in dendrite, neuronal cell 
bodies and in terminal regions (Pickel, 2006). Using FRET experiments, Marcellino et al. 
(2008) have also shown that CB1/D2 receptors form a heterodimeric complex. 
In addition, at the cellular level Glass and Felder (1997) have demonstrated that co-activation 
of CB1 and D2 receptors decreases the inhibition of cAMP, suggesting that an interaction 
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between CB1 and D2 receptors allows a switch in G-protein coupled from Gαi to Gαs. 
Similarly, a chronic activation of D2 receptors appears to change CB1 coupling to Gs 
proteins. 
In vitro studies showed direct interactions between µ-receptors and CB1 receptors, with a co-
localization and formation of functional heterodimers. Using cells transfected with both 
receptors, it was found that WIN produced a non-competitive antagonist of morphine-induced 
G protein activity, while a CB1 inverse agonist increased agonist stimulation of the µ-receptor 
(Canals and Milligan, 2008).  
The functional cross-talk between the ECS and others has been suggested to be involved in 
numerous brain disorders. For this reason, characterization of the domains involved in the 
heteromerization between CB1 receptors and different GPCRs might be relevant to determine 
how these interactions can contribute to the pathophysiology of brain diseases.  
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1.3 Rimonabant 
Rimonabant, also known as SR141716A or SR (trade name Acomplia), was the first selective 
central CB1 receptor antagonist, developed by Sanofi-Aventis, indicated for the treatment of 
obesity. Obesity is one of the most relevant eating disorders in industrialised countries and is 
defined as abnormal or excessive fat accumulation (body mass index, BMI >30 kg/m
2
) that 
may impair health and longevity. CB1 receptors are believed to play a role in controlling food 
consumption. Based on the promise that cannabinoid receptor agonists stimulate appetite, it 
resulted that a block of cannabinoid receptors in the brain might reduce the appetite. 
Compounds with potential inhibitory activity against this receptor were thus screened and SR 
emerged from this screening process as the most promising compound. 
The beneficial effects of SR were confirmed in a series of clinical studies, including pivotal 
phase III trials that involved over 6,000 obese subjects in both the US and Europe (Verty et 
al., 2009). 
Two-year data from the phase III multicentre Rimonabant In Obesity (RIO) trial, which 
compared this drug at doses of 5 mg and 20 mg to a placebo with respect to weight reduction 
and prevention of weight gain, showed that the positive results seen after a year's treatment 
were sustained over the full two-year trial period. SR was found to induce effective lipolysis, 
reduce hepatomegaly, and to improve dyslipidemia by reducing triglycerides, free fatty acids, 
and total cholesterol levels and by increasing the HDL/LDL ratio. 
On 21 June 2006, the European Commission approved the sale of SR in all 25 member states 
of the European Union. 
In the United States SR was submitted to the Food and Drug Administration (FDA) for 
approval. However, SR safety data indicated an increased risk for suicidal ideation in patients 
at the highest dose of 20 mg. The FDA Committee expressed concerns about the increased 
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risk of psychiatric and neurological adverse events. 
In October 2008, the European Medicines Agency’s Committee for Medicinal Products for 
Human Use stated that the risks of SR outweighed its beneficial effects. The Agency then 
recommended suspension of the product from the UK market, and Sanofi removed the drug 
from the market. 
As reported in par 1.2.2, SR was the first selective and orally active CB1 receptor antagonist 
(Rinaldi-Carmona et al., 1994), which blocks agonist-induced activation of cannabinoid CB1 
receptors in a competitive manner and binds with significantly greater affinity to cannabinoid 
CB1 than cannabinoid CB2 receptors. The possibility that SR also acts as an “inverse 
agonist”, inhibiting CB1 receptor-constitutive activity, was suggested by Compton et al. 
(1996), who showed that the in vivo injection of high doses (3 mg) of SR stimulated motor 
activity. Since then, inverse cannabinoid mimetic effects of SR have been observed in 
experiments performed both in vivo and in vitro (Pertwee, 2005).  
The following paragraphs report selected examples concerning the in vivo and in vitro 
antagonist as well as agonist inverse effects of SR mediated by CB1- and not CB1-receptors 
and/or by its interaction with other receptors.  
 
 
1.3.1 In vivo studies 
The first in vivo studies on SR have shown that it antagonizes discriminative stimulus 
properties, the hypothermic, motor and antinociceptive effects of cannabinoids in rodents and 
non-human primates (Compton et al., 1996, Wyley et al. 1995, Nakamura-Palacios et al., 
1999). Specifically, intravenous injection of SR in mice inhibited THC-induced hypothermia, 
hypoactivity and antinociception with doses <3 mg/kg. It also antagonized the hypothermic 
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effects of CP55940 and of WIN in rodents, an effect observed for 18h after oral 
administration (Mansbach et al., 1996; Rinaldi-Carmona et al., 1994). However, SR was 
found to not antagonize the hypothermia and analgesia produced by administration of AEA 
(Welch et al., 1998). SR also blocked the hypomotility induced by THC, CP55940 and WIN, 
and when given by intracerebrovascular administration blocked catalepsy Lichtman and 
Martin, 1996).  
SR also reverted the thermal- and chemical-antinociceptive effects of THC, as well as the 
effects of WIN in mice (Compton et al., 1996; Rinaldi-Carmona 1994) and both THC and 
WIN in rhesus monkeys (Vivian et al., 1997). Moreover, SR antagonized the “pop corn” 
effect in mice, the barrel rotations in rats induced by WIN (Souilhac et al, 1995) and turning 
behaviour produced by unilateral intrastriatal injections of cannabinoid agonists (Vivian et al, 
1997). In addition, SR blocked the hypotension and bradycardia induced by THC, CP55940 
and WIN in rats and guinea pigs and precipitated a withdrawal syndrome in rats made tolerant 
to THC. Finally, other studies have shown that SR antagonized the cannabinoid-induced 
effect on learning and memory. In particular, SR produced a rightward shift in the 
cannabinoid dose-effect curves for response rate in a repeated acquisition procedure. This 
effect was not observed with doses of SR >1 mg/kg, suggesting that other actions of SR may 
disrupt its antagonist effects of CB1 receptors on learning (Nakamura-Palacios et al., 1999). 
SR blocks the hypotension and bradycardia induced by THC, CP55940 and WIN in rats and 
guinea pigs and precipitates a withdrawal syndrome in rats made tolerant to THC (Rubino et 
al., 1998). 
Despite all these findings, several studies have shown that there are in vivo actions of SR that 
cannot be explained by antagonism on CB1 receptors. In particular, high doses of SR (10 
mg/kg, i.p.) disrupted learning memory in rats previously treated with THC. In contrast, in a 
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range of doses between 0.03-3 mg/kg, SR improved social short-term memory in adult and 
aged rodents (Terranova et al., 1996).   
SR has been found to have effects on food intake, with doses from 0.03 mg/kg to 3 mg/kg 
reducing spontaneous sucrose intake in food-restricted rats. It was also shown to reduce 
sucrose drinking in food-restricted rats after one week of habituation in a dose dependent-
manner (Arnone et al., 1997). Recently, Ward et al. (2009) have shown that SR decreased 
sweet-tasting liquid food intake in a dose-dependent manner in both male and female wild-
type and knock-out mice.  
Finally, behavioural studies have displayed that SR also exerts opposite in vivo effects to CB1 
receptor agonists, since it produces hyperalgesia (Richardson et al., 1997; Pertwee et al., 
2000), a decrease in food consumption (Colombo et al., 1998; De Vry et al., 2004; Verty et 
al., 2004) and an improvement in memory (Lichtman et al., 2002; Terranova et al., 1996).  
Experiments performed with CB1-KO mice support the hypothesis that SR produces at least 
some of its inverse agonist by binding to CB1 receptors. Thus, SR enhances an electrically 
evoked release of noradrenaline in vasa deferentia and reduces food intake from WT mice, but 
not in CB1R KO. On the contrary, there are also reports showing that reduced food intake and 
increased severity of induced colitis, effects opposite to those produced by CB1R agonists, 
are observed both in SR-treated CB1-KO and in SR-treated WT mice (Di Marzo et al., 2001; 
Massa et al., 2004). Furthermore, SR at high doses produced  significant anxiolytic effects in 
CB1- KO mice. 
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1.3.2 In vitro studies  
As mentioned, SR competitively blocked the specific binding of the CB1 radioligand agonist 
[
3
H]CP55,940 to CB1 and CB2 receptors, with a nanomolar affinity for CB1 receptors in 
human and rat brains, and a micromolar affinity for the CB2 receptor. In competitive studies, 
unlabelled SR was found to have IC50>1 μM for several other receptors such as: adenosine A1 
and A2, α1, α2, β1 and β2 adrenoceptors, histamine H1, H2 and H3, serotonin 5HT1A, 5HT2 and 
5HT3 (Rinaldi-Carmona, 1994). In functional assays with isolated tissue preparations, SR 
antagonized the effects induced by cannabinoids; for instance in guinea pig isolated ileal 
muscle-myenteric preparations, as well as in mouse isolated vas deferens and urinary bladder 
preparations, SR reverted the cannabinoid agonist inhibition of the twitch response evoked by 
electrical stimulation (Pertwee et al., 1997; Rinaldi-Carmona, 1996). Further, it antagonized 
WIN-mediated inhibition of the depolarization-induced release of dopamine and 
norepinephrine from guinea pig hippocampal slices (Schlicker et al., 1996). SR reverted the 
WIN-mediated inhibition of adenylyl cyclase activity in synaptosome preparations from the 
rat brain (Nakamura-Palacios et al., 1999). In all these assays, SR behaved as a competitive 
antagonist with affinities in the nanomolar range that are consistent with its ability to interact 
with the CB1 receptor. 
In contrast Landsman et al. (1997) showed that SR is a rather inverse agonist in membrane 
prepared from Chinese hamster ovary (CHO) transfected with human CB1 receptor, as 
assessed by the [
35S]GTPγS binding assay. Inverse agonist effects of SR were characterized 
using ligand-modulated [
35S]GTPγS binding, a methodology performed to investigate drug 
actions directly on G protein. Specifically, SR inhibited [
35S]GTPγS binding in CB1 
transfected cell lines (MacLennan et al., 1998; Breivogel et al., 2001), in neuronal cells, and 
in the rat and mouse brain (Breivogel et al., 2004; Bouaboula et al., 1997; Sim-Selley et al., 
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2001). Accordingly, SR produces a decrease in MAPK activity and an increase in evoked 
neurotransmitter release (Gifford et al., 2000; Breivogel et al., 2004; Schlicker et al., 2001) in 
basal cyclic AMP (cAMP) and forskolin stimulated cAMP production in the heterologous 
expression system, neuronal cell lines and rat or human brain membranes (Bouaboula et al., 
1997; Felder et al., 1998; Mato et al., 2002; Meschler et al., 2000). Moreover, Pan et al. 
(1998) showed that SR increased N-type Ca
2+
 currents in superior cervical ganglion neurons 
by inhibiting the tonically active state of CB1 receptors.   
In addition, when tested alone at concentration >1 µM SR decreased [
35S]GTPγS basal 
binding in membrane from CB1-WT and CB1-KO mice, and this effect was not blocked by 
the CB1 receptor neutral antagonist (O-2050), suggesting that the inverse agonist effects of 
SR are CB1 receptor independent (Cinar and Szucs, 2009). 
Recently, Erdozain et al. (2012) found that SR at concentrations of > 1 μM acted as inverse 
agonists in the post-mortem human brain, demonstrating that this effect is not mediated by the 
CB1 receptor. SR inhibited basal [
35S]GTPγS binding to human cortical membranes in a 
concentration-dependent manner and, in the presence of 1 μM, did not modify the inhibitory 
curve of SR. Moreover, the neutral CB1 receptor antagonist, O-2050, at 10 μM and 100 μM 
fails to affect the inhibition produced by SR on basal [
35S]GTPγS binding. These data support 
the hypothesis that the inverse agonist effect of SR is not CB1 receptor-mediated. In order to 
exclude that SR might bind to a site distinct from the ortosteric agonist-binding site, or that its 
effects might be due to an allosteric modulation, the effect of Org27569, an allosteric 
modulator of the CB1 receptor was tested. This compound did not modify the inhibition of the 
basal G protein signaling produced by SR excluding the possibility that the SR effects are 
mediated by an interaction with a CB1 allosteric site.   
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1.3.3 Effects of SR on other receptors 
Savinainen et al. (2003), using the [
35S]GTPγS binding assay, demonstrated that SR inhibited 
G protein activity in brain membranes prepared for the A1 receptor.  
In 2004, another study on a rat Parkinson’s model, showed that after the infusion of SR into 
denervated striatum nerves, ipsilateral rotation in hemiparkinsonian rats was reduced, leading 
to an improvement in motor performance (Pinna et al., 2014). The results suggest that SR had 
opposite effects on D1 and D2 receptor function, leading to a positive modulation of motor 
processes induced by D1 receptor stimulation, but to a reduction of D2 dopamine receptor 
function. 
Accordingly, Alonso et al. (1999) reported that SR reduced D2 receptor function in rat 
striatum. Crunelle et al. (2013) found that chronic administration of SR (1–3 mg/kg/day) 
dose-dependently increased D2 receptor availability in the dorsal and ventral striatum. Since 
the latter region regulates food intake, the effects of SR observed in this study might be 
related to increasing D2 receptor availability.  
In addition, acute treatment with SR reduced dopamine released in the nucleus accumbens 
after food and drug administration (Melis et al., 2007). The effects of SR on the striatal 
dopaminergic system need further investigation.  
Indeed, a recent in vitro study showed that the constitutive activity of CB1 receptors 
negatively regulates the function of co-expressed μ-opioid receptors (Canals and Milligan, 
2008). 
Accordingly, strong evidence that SR might act on receptors other than the CB1 receptors was 
provided by Cinar et al. (2009). They found that SR completely inhibited and decreased G 
protein activation induced by the µ-receptor agonist Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol Tyr-D-
Ala-Gly-(NMe)Phe-Gly-ol (DAMGO) in the cortex of CB1-WT and CB1-KO mice, and in 
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CHO expressing μ-opioid receptors (Cinar and Szucs, 2009).  These authors confirmed the 
hypothesis that the inverse agonist effect of SR was not CB1 receptor-independent and 
possibly even non-receptor-mediated. Another study reports that SR bound to the µ-receptor 
with a significant affinity and antagonized the ability of morphine to inhibit the activity of 
adenylyl cyclase in CHO cells stable transfected with µ-receptors. Interestingly, 10 µM of SR 
inhibited G protein basal activity in CHO-WT cells that are devoid of µ-receptors (~20% on 
the [
35S]GTPγS basal binding). Moreover a pre-treatment of SR attenuated morphine 
analgesia in B6/SJL mice and in C57BL/6J mice. Altogether, these results demonstrate that 
SR might act on different GPCRs with a multitude of effects in in vivo testing (Seely et al., 
2012). 
Finally, a very recent study showed that in competition binding experiments, SR at a low 
micromolar range in CHO cells transfected with rat kappa opioid receptor (CHO-rKOR), 
inhibited KOR agonist [
3
H]U69593 binding and specifically reduced KOR basal activity at 
lower micromolar concentrations in [
35
S]GTPgS binding assays. The decrease of G protein 
basal activity induced by SR was higher at 10 μM compared with 1 μM, but interestingly only 
the effect induced by the lower dose of SR was reverted by nor-BNI (the κ-receptor 
antagonist). Thus the inverse agonistic effect of Rimonabant at 10 μM concentrations is not 
KOR related (Zador et al., 2015). 
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1.4 Aim of the study 
 Several possible mechanisms, such as modulation of the constitutive activity of the CB1 
receptor, antagonism at CB1 receptors of endogenously released endocannabinoids, and CB1 
receptor-independent mechanisms, either through another receptor or by a receptor-
independent mechanism have been proposed to explain SR induced inverse agonist effects.  In 
addition, recent findings have led to the hypothesis that SR might directly inhibit G protein 
activity by a non-receptor-mediated mechanism.  
Based on these premises, the present study aimed to determine whether the CB1 receptor-
independent effects of SR are mediated via GPCRs, in particular GABAB and dopamine D2 
receptors, that share the same Gαi/o signaling pathways, or if SR acts directly on G protein. 
Hence this project was carried out in different phases in order to characterize: 
 
1. Effects of SR on G-protein activity using the [35S]GTPγS binding assay in native and 
recombinant systems containing CB1, GABAB and D2 receptor populations (rat and 
mouse membrane homogenates) and in CHO stable transfected with GABAB 
receptors, D2 receptors and in CHO non-transfected cells; and the effects of SR on G 
protein activity in systems lacking CB1 and GABAB receptors (CB1 and GABAB-
knockout mice). 
 
2. Effects of SR on G-protein heterodimerization and subunit rearrangement using the 
BRET assay in recombinant systems. 
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3. Effects of SR on G-protein effectors using different techniques such as BRET to 
monitor adenylyl cyclase activity, and electrophysiological recordings in both native and 
recombinant systems. 
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Chapter 2. Materials and Methods 
 
2.1 Chemicals 
5’-O-(3-[35S]thiotriphospate) ([35S]GTPS) (1250 Ci/mmol) was purchased from PerkinElmer 
Life , GABA, GDP, guanosine 5′-O-(3-thiotriphosphate) (GTPγS), were obtained from Sigma 
/RBI (Natick, MA). R(-)baclofen, CGP54626, quinpirole, L-Sulpiride, WIN55,212-2 (WIN), 
AM251 were purchased from Tocris Bioscience (Ellisville, MO). [35S]GTPγS (125 Ci/mmol), 
and [3H]CGP54626 (85 Ci/mM) were obtained from PerkinElmer Life and American 
Radiolabeled Chemicals Inc. (St. Louis, MO), respectively. SR1417161A (SR) was a 
generous gift from Sanofi-Aventis. 
 
2.2 Animals 
Male Sprague-Dawley rats and DBA mice (Charles River Laboratories, Calco, Italy), 
weighing 200 to 250 and 17 to 20 g, respectively, were used. Rats and mice were housed 4 
and 20/cage, respectively, in standard plastic cages with wood chip bedding, at temperature of 
22 ± 2 °C and 60% humidity and under a 12 h light/dark cycle (lights on from 7.00 a.m.). Tap 
water and standard laboratory rodent chow (Mucedola, Settimo Milanese, Italy) were 
provided ad libitum in the home cage. 
Mutant mice with the CB1 receptor gene deleted (CB1-KO) were obtained and genotyped as 
previously described (Marsicano et al., 2002), while GABAB(1)-KO (GABAB(1)-/-) mice were 
generated on inbred Balb/c strain background (Schuler et al., 2001). 
The animals were housed in a temperature- and light-controlled room. Lighting was ensured 
in a 12-h cycle, and food and water were available ad libitum.  
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2.3 Tissue preparation 
Male rats (250 g) were sacrificed by decapitation, their brains rapidly removed and cerebral 
cortices and striata were dissected on ice. Cortical tissues were homogenized using a glass-
teflon homogenizer (Glass-Col, Terre Haute, IN) in 15 volumes (v/w) of ice-cold 0.32 M 
Sucrose and 1 mM EDTA. The homogenate was centrifuged at 1000 x g for 10 min, then the 
supernatant was collected and re-centrifuged at 20000 x g for 20 min. The pellet was re-
suspended in 20 volumes (v/w) of ice-cold distilled water, homogenized using a Polytron 
homogenizer, and centrifuged at 8000 x g for 20 min. The last centrifugation of supernatant 
together with the buffy layer was performed at 45000 x g for 40 min, then the supernatant was 
discarded and the final pellet was frozen and stored at -80°C for at least 24 h before use.  
For striata, tissues were homogenized in 20 volumes of buffer (50 mM Tris-HCl, 3 mM 
MgCl2 and 1 mM EGTA, pH 7.4). The homogenate was centrifuged twice at 48,000 x g at 
4°C for 10 minutes, resuspended in homogenization buffer and frozen at -80°C until use.  
The Bradford (1976) protein assay was used for protein determination using bovine serum 
albumin as a standard according to the supplier protocol (Bio-Rad, Milan, Italy) 
 
2.4 [35S]GTPγS binding assay in rat and mice membranes 
On the day of experiment, for GABAB-stimulated [35S]GTPγS binding, rat cortex membranes 
were thawed at 4°C and suspended in 20 volumes (v/w) of Krebs-Henseleit buffer (143 mM 
NaCl, 50 mM Tris-HCl, 5.9 mM KCl, 1.2 mM MgSO4 and 2.5 mM CaCl2, pH 7.4), 
homogenized, incubated at RT for 10 min an then centrifuged for 10 min at 40000 x g at 4°C. 
This step was repeated for three times. Afterward membranes were incubated in ice-cold 
water for 1h on ice, and then centrifuged for 20 min at 18000 x g at 4°C to obtain the final 
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pellet. The final pellet was re-suspended in assay buffer, containing 50 mM Tris-HCl buffer, 
pH 7.7; 10 mM MgCl2; 1.8 mM CaCl; 100 mM NaCl; 30 µM guanosine 5’-diphosphate, to a 
final concentration of 20 µg of protein. Membrane homogenates and drugs were pre-
incubated in PerkinElmer PicoPlates 96 (300 µl volume) for 30 min at 30°C. The main 
incubation was subsequently started by the addition of [35S]GTPγS to a final concentration of 
0.2 nM. After 40-min incubation at 30°C, the samples were filtered using a PerkinElmer 
UniFilter-GF/B, washed twice with 300 µl of buffer, and dried for 1 h at 30°C.   
For CB1-stimulated [35S]GTPγS binding, cortical membranes (10-15 µg of proteins) were 
incubated in assay buffer (50 mM Tris-HCl, 3 mM MgCl2, 0.2 mM EGTA and 100 mM NaCl, 
BSA 0.1%, pH 7.4) at 30°C for 1 h with 30 µM GDP and 0.05 nM [35S]GTPγS in a final 
volume of 1 ml. After incubation, the samples were filtered using a PerkinElmer UniFilter-
GF/B, washed twice with 1 ml of buffer and dried for 1 h at 30°C. 
For D2-stimulated [35S]GTPγS binding, striatal membranes (20 µg of proteins) were pre 
incubated in assay buffer (20 mM K-HEPES, 7 mM MgCl2, 1 mM EDTA, 1mM DTT and 
100 mM NaCl, pH 7.6) at RT for 30 min with 300 µM GDP. The main incubation was 
subsequently started by the addition of [35S]GTPγS to a final concentration of 0.1 nM in a 
volume of 300 µl. After 60 min of incubation at 35 °C, the samples were filtered using a 
PerkinElmer UniFilter-GF/B, washed twice with 1 ml of buffer (20 mM K-HEPES and 100 
mM NaCl, pH 7.6), and dried for 1 h at 30°C.  
The radioactivity on the filters was counted in a liquid microplate scintillation counter 
(TopCount NXT; PerkinElmer Life and Analytical Sciences) using 50 µl of scintillation fluid 
(Microscint 20; PerkinElmer Life and Analytical Sciences). Basal binding was assessed in the 
absence of agonist and in the presence of GDP, and nonspecific binding was measured in the 
presence of 10 µM unlabeled GTPγS. The stimulation by agonist was defined as a percentage 
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increase above basal levels (i.e., [disintegrations per minute (agonist) – disintegrations per 
minute (no agonist)/(disintegrations per minute (no agonist)] x 100). Data are reported as 
means S.E.M. of three to six experiments, performed in triplicate. Nonlinear regression 
analysis of concentration-response data was performed using Prism 2.0 software (GraphPad 
Prism) to calculate Emax and EC50 values. 
  
2.5 [3H]CGP54626 binding assay 
[3H]CGP54626 binding were performed as previously described (Castelli et al., 2012). 
Briefly, binding was carried out using 50 µg of membrane proteins, 2 nM [3H]CGP54626 in a 
volume of 1 ml at 22–24°C for 30 min. Nonspecific binding was estimated in the presence of 
10 µM unlabeled CGP54626. Free ligand was separated from bound ligand by rapid filtration 
through Whatmann GF/B glass filters using a Brandel 30-samples harvester (Brandel Inc., 
Gaithersburg, MD). Filters were then rinsed twice with ice-cold Krebs-Henseleit buffer. 
Filter-bound radioactivity was counted in a liquid scintillation counter (Tri-carb 1600; 
PerkinElmer Life and Analytical Sciences) using 3 ml of scintillation fluid (Ultima Gold MV; 
PerkinElmer Life and Analytical Sciences). [3H]CGP54626 displacement curves were 
determined using increasing concentrations (from 1 nM to 0.5 mM) of SR and increasing 
concentrations (from 0.1 nM to 0.1 µM) of the unlabeled CGP54626. 
The calculation of IC50 was performed by nonlinear curve fitting of the concentration-effect 
curves using GraphPad Prism (GraphPad Software Inc., San Diego, CA). The F test was used 
to determine the best approximation of a nonlinear curve fitting to one or two site model (P < 
0.05). 
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2.6 Cell culture, transfection and membrane preparation for [35S]GTPγS binding 
assay  
Culture and maintenance of CHO-K1 cells stably expressing human GABAB(1b,) and rat 
(CHO-GABAB2) was performed as described (Urwyler et al., 2001) and maintained in 
DMEM supplemented with 500 µM L-glutamine (Sigma), 40 mg/ml L-proline (Sigma), 0.5 
mg/ml genecitin , 0.25 mg/ml zeocine, (Invitrogen) and 10% FBS in a humidified atmosphere 
of 5% CO2 at 37 °C.  
Preparation of membranes from CHO-GABAB for [35S]GTPγS binding assay was performed 
as previously described (Urwyler et al., 2001). Briefly, CHO-GABAB2 cells were grown to 
80-90 % confluency in 145-cm Petri dishes. Then, the culture dishes were washed twice with 
ice-cold PBS, 10 mM HEPES buffer, pH 7.4 was added to the plates and cells were scraped 
off. Crude membranes from several dishes were collected and centrifuged at 4°C for 20 min at 
15000 x g. The pellet was re-suspended in 10 ml HEPES buffer and homogenized using a 
glass- glass homogenizer (10 strokes). Afterward, the suspension was centrifuged (18000 x g, 
30 min, 4° C), and the pellet was re-suspended in a small volume of buffer and homogenized 
again (20 strokes). Aliquots were frozen in liquid nitrogen and stored at -80 °C until use. 
 CHO-K1 cells stably expressing D2 receptors were prepared using Lipofectamine 2000 
(Invitrogen) as described (Newman-Tancredi et al., 1999).  Briefly, CHO-K1 cells were 
cultured to 80% confluence (3x106 cells in 100-mm dishes) and incubated for 6 h with 30 µg 
of pcDNA3.1 (Zeo) plasmid containing the cDNA encoding for the human D2-long receptor 
(gently gift from O Civelli, Dept. of Pharmacology, University of California, USA) and 60 µl 
of Lipofectamine reagent in serum-free Opti-MEM. Selection antibiotic (0.3 mg/ml zeocin) 
was added to the cell culture medium 48 h after transfection, and surviving colonies were 
picked 14 days after beginning selection. To confirm D2-long expression, competition and 
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saturation binding experiments using [3H]YM09151-2, the specific D2 receptor antagonist, 
were performed as previously described (Vanhauwe et al., 1999). The clone expressing the 
highest level of specific D2-long receptors was selected, designated as CHO-D2 cells, 
maintained in DMEM containing 300 µg/ml zeocin and used throughout the study. 
For membranes preparation for GTPγS binding, CHO-D2 cells were grown in a 145-cm Petri 
dishes. At 90% confluence, 5 mM sodium butyrate was added to increase the receptor 
expression level and the cells were further incubated for 24 h (Vanhauwe et al., 1999). Then, 
medium was removed, the culture dishes were washed once with 5 ml of ice-cold PBS and 
stored at -80°C until use. Cells on Petri dishes were thawed, cells were harvested using 5 ml 
of 10 mM Tris-HCl (pH 7.4), 1 mM EDTA, 1 mM 4-(2-amino- ethyl)benzene-sulfonyl-
fluoride hydrochloride and homogenized with a dual homogenizer (motor-driven Teflon 
pestle and conical glass tube). Then homogenate was centrifuged (10 min at 1000 x g at 4°C), 
and the resulting pellet was re-suspended and centrifuged again (10 min at 1300 x g at 4°C). 
Both supernatants were pooled and centrifuged at 50000 x g for 1h at 4°C. The resulting 
pellet was re-suspended in 50 mM TrisHCl (pH 7.4), containing 10% glycerol and stored in 
aliquots at -80°C until use.  
 
2.7 [35S]GTPγS binding assay in CHO, CHO-GABAB and CHO-D2 cell membranes 
On the day of the experiment, the frozen membranes were thawed and then centrifuged for 10 
min at 12000 x g and 4°C. The pellet was resuspended in 1 ml of ice-cold distilled water and 
incubated for 1 h on ice. After a further centrifugation as before, the final pellet was re-
suspended in the appropriate amount of assay buffer.  
For CHO-GABAB stimulated [35S]GTPγS binding, membranes (20 µg of proteins) were 
incubated in assay buffer (50 mM Tris-HCl, 10 mM MgCl2, 0.2 mM EGTA and 100 mM 
	Chapter 2. Materials and Methods 56 
NaCl, 2 mM CaCl2, pH 7.7) at 22-24°C for 1 h with 30 µM GDP and 0.2 nM [35S]GTPγS in a 
volume of 0.3 ml. After incubation, the samples were filtered using a PerkinElmer UniFilter-
GF/C, washed twice with 1 ml of buffer and dried for 1 h at 50°C (Urwyler et al., 2001).  
For CHO-D2 and CHO non transfected stimulated [35S]GTPγS binding, membranes (10 µg of 
proteins) were pre-incubated in assay buffer (50 mM K-HEPES, 10 mM MgCl2, 100 mM 
NaCl, 0.1% BSA, pH 7.4) for 30 min at 30°C with 10 µM of GDP. The main incubation was 
subsequently started by the addition of [35S]GTPγS to a final concentration of 0.1 nM. After 
90 min incubation at 30°C, the samples were filtered using a PerkinElmer UniFilter-GF/B, 
washed twice with 300 µl of buffer 50 mM HEPES, pH 7.4, and dried for 1 h at 30°C. The 
radioactivity on the filters was counted in a liquid microplate scintillation counter (TopCount 
NXT; PerkinElmer Life and Analytical Sciences) using 50 µl of scintillation fluid (Microscint 
20; PerkinElmer Life and Analytical Sciences). 
 
2.8 Bioluminescence resonance energy transfer (BRET) measurements 
Human Embryonic Kidney 293T (HEK293T) cells or CHO-GABAB cells were growing in 
10-cm culture dishes at 37°C, 5% CO2, in DMEM supplemented with 10% FBS. Transient 
transfections of different constructs were carried out using Lipofectamine 2000 (Invitrogen), 
according with manufacturer’s instruction. 48 or 24 hours after transfection, cells were 
washed twice with PBS, incubated in the presence or absence of SR (different 
concentrations), for 1 h before substrate addition in a 96-well microplate (Corning 
Incorporated-Costar).  
BRET1 between Renilla luciferase (Rluc) and Venus or Yellow Fluorescent Protein (YFP) 
was measured after the addition of the Rluc substrate Coelenterazine h (NanoLight 
Technologies) with a final concentration of 5 µM. BRET1 readings were collected (except in 
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kinetics experiments; see below) at the appropriate wavelengths using Infinite® F500 
microplate reader (Tecan). The BRET1 signal was calculated as the ratio of the light emitted 
by YFP or Venus (530–570 nm) over the light emitted by Rluc (370–470 nm). BRET1 signal 
values were corrected by subtracting the background signal detected when Rluc-tagged 
construct was expressed alone from the signal detected in cells coexpressing both Rluc- and 
Venus- or YFP-tagged constructs (Net BRET). Data were analyzed using Microsoft Excel and 
plot using GraphPad PRISM. Statistical significance was assessed using one-way analysis of 
variance (ANOVA) followed by Bonferroni’s test where appropriate. 
 
2.9 BRET in CHO GABAB transfected with Gαo-Rluc and Gγ2-Venus 
CHO cells stably expressing GABAB1 and GABAB2 were transfected with plasmids encoding 
Gαo-Rluc, Venus-Gγ2, FLAG-Gβ2 (gift from Pin J.P., Institute de Génomique Fonctionnelle, 
Montpellier) and were seeded into 96- well microplates. 24 h after transfection, cells were 
washed with PBS and the measurement was initiated using Tecan after 10 minutes of 
incubation of 5 µM Coelenterazine h. 10 µM GABA was injected after 29 cycles of reading, 
and CGP54626 was injected after 99 cycles. Luminescence and fluorescence signals were 
detected sequentially with an integration time of 200 ms. The BRET ratio was calculated as 
the ratio of light emitted by Venus-Gγ2 (530-570 nm) over light emitted by Gαo-Rluc (370-
470 nm) and corrected by subtracting ratios obtained with the Rluc fusion protein alone. The 
results were expressed in mBRET units (BRET x 1000). The curves were fitted using 
GraphPad Prism 5.0 (“Plateau followed by one-phase decay”). ΔBRET was calculated as the 
difference between the basal and the plateau of BRET signal. 
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2.10  BRET in HEK293 transfected with Gαi-Venus and D2-Rluc  
HEK293T were transfected with D2-Rluc (gift from Kern A., The Scripps Research Institute 
Florida, USA) and Gαi-60Venus or Gαi-91Venus or Gαi-121Venus (gift from Lambert N., 
Georgie Regents University Augusta, USA) and were seeded into 96- well microplates. 
48 h after transfection, cells were washed with PBS and the measurement was initiated using 
Tecan after 10 minutes of incubation of 5 µM Coelenterazine h. 100 µM Quinpirole was 
injected after 29 cycles of reading. Luminescence and fluorescence signals were detected 
sequentially with an integration time of 200 ms. The BRET ratio was calculated as the ratio of 
light emitted by Venus-Gαi (530-570 nm) over light emitted by D2-Rluc (370-470 nm) and 
corrected by subtracting ratios obtained with the Rluc fusion protein alone. The results were 
expressed in mBRET (BRET x 1000). 
 
2.11 BRET in HEK293 transfected with Gαi-Venus and Gβ1-Rluc or Gγ2-Rluc 
HEK293T were transfected with Gαi-60Venus, Gαi-91Venus or Gαi-121Venus and Gβ1-Rluc or 
Gγ2-Rluc (gift from Jacquier V., University of Basel, Switzerland) and were seeded into 96- 
well microplates. 24 h after transfection, cells were washed with PBS and the measurement 
was initiated on Tecan after 10 minutes of incubation of 5 µM Coelenterazine h. 
Luminescence and fluorescence signals were detected sequentially with an integration time of 
200 ms. The BRET ratio was calculated as the ratio of light emitted by Venus-Gαi (530-570 
nm) over light emitted by Gβ1-Rluc or Gγ2-Rluc (370-470 nm) and corrected by subtracting 
ratios obtained with the Rluc fusion protein alone. The results were expressed in mBRET 
(BRET x 1000). 
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2.12 BRET in HEK293 with CAMYEL sensor 
HEK293T were transfected with Myc-GABAB1a, Myc-GABAB2 or D2-HA and CAMYEL 
(purchased from American Type Culture Collection, Manassa, VA, USA) and were seeded 
into 96- well microplates and were seeded into 96- well microplates. 24 h after transfection, 
cells were washed with PBS and the measurement was initiated using Tecan after 10 minutes 
of incubation of 5 µM Coelenterazine h.  
0.5 µM Forskolin was injected after 19 cycles of reading, GABA 100 µM or quinpirole 10 
µM were injected after 99 cycles. Luminescence and fluorescence signals were detected 
sequentially with an integration time of 200 ms. The BRET ratio was calculated as the ratio of 
light emitted by YFP (530-570 nm) over light emitted by Rluc (370-470 nm) and corrected by 
subtracting ratios obtained with the ratio of light emitted by YFP (530-570 nm) over light 
emitted by Rluc (370-470 nm) measured on HEK293T transfected with CAMYEL only. The 
curves were fitted using GraphPad Prism 5.0 (“Plateau followed by one-phase association”). 
The amplitude-weighted mean time constant (tau CAMYEL activity) was obtained by fitting 
BRET recovery phase to a double exponential function.  ΔBRET was calculated as the 
difference between the basal and the plateau of BRET signal. 
 
2.13 Whole cell voltage clamp recordings from dopamine neurons 
Whole cell patch clamp recordings from VTA DA cells were as described previously (Melis 
et al., 2006). Briefly, male Sprague Dawley rats (Harlan Nossan, San Pietro al Natisone, Italy) 
or CB1-KO and littermate wild-type (WT) control mice were anesthetized with halothane and 
killed. Recordings were made from horizontal slices superfused with artificial cerebrospinal 
fluid (ACSF, 37° C) saturated with 95% O2 and 5% CO2 containing (in mM): 126 NaCl, 1.6 
KCl, 1.2 NaH2PO4, 1.2 MgCl2, 2.4 CaCl2, 18 NaHCO3, and 11 glucose. Evoked field 
	Chapter 2. Materials and Methods 60 
potential recordings were as described previously (23). All the drugs were dissolved in 
DMSO. The final concentration of DMSO was < 0.01 %. Statistical significance was assessed 
using one- or two-way analysis of variance (ANOVA) for repeated measures followed either 
by Dunnett’s or t test (with Welch’s correction), where appropriate. 
 
2.14 Whole cell patch clamp recordings from CHO cells  
CHO cells expressing GABAB1 and GABAB2 were transiently transfected with Kir3.1/3.2 
plasmids encoding using Lipofectamine 2000 (Invitrogen), according with manufacturer’s 
instruction. 24 hours after transfection experiments on CHO cells were performed at room 
temperature as previously described (Schwenk et al., 2010). During recording CHO cells were 
continuously superfused with an extracellular solution composed of (in mM): 145 NaCl, 2.5 
KCl, 1 MgCl2, 2 CaCl2, 10 HEPES, 25 Glucose; pH 7.3, 323 mOsm. Patch pipettes had 
resistances between 3-4 MΩ when filled with intracellular solution composed of (in mM) 
107.5 potassium gluconate, 32.5 KCl, 10 HEPES, 5 EGTA, 4 MgATP, 0.6 Li4GTPγS, 10 Tris 
phosphocreatine; pH 7.2, 297 mOsm. Series resistance (< 5 MΩ) was compensated by 80%. 
Kir3 responses induced by GTPγS were recorded with an Axopatch 200B patch-clamp 
amplifier (Molecular Devices, USA); filtering and sampling frequencies were set to 1 kHz 
and 5 kHz, respectively. Data analyses were done with pClamp 10 (Molecular Devices, USA). 
Data are given as mean ± SD. Statistical significance was assessed using t-test. SR was 
dissolved in intracellular solution at a final concentration of 10 µM. Before the recording, 
CHO cells were preincubated in the extracellular solution with or without the drug for 45 
minutes at room temperature (22 - 24°C). 
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Chapter 3. Results 
 
3.1 Effect of SR on G-protein activity in native and recombinant systems 
 
3.1.1 SR inhibits G-protein basal activity in rat cortical and striatal membranes  
As shown in Fig. 12, SR dose-dependently, and significantly reduced the basal activity of 
[
35S]GTPγS with a potency of 3.9 ± 0.45 μM (IC50), reaching maximal inhibition (Imax, 
approximately 48%) at 100 μM in the rat cortical membranes (A). In striatal membranes, non-
linear regression analysis of SR concentration-response curves showed that maximal 
inhibition of basal [
35S]GTPγS activity was 60% and half-maximal inhibition was obtained at 
3.67 ± 0.5 μM (B). 
           A          B 
 
 
Figure 12. Effect of SR on basal [
35
S]GTPγS binding in rat cortical membranes (A) and striatal 
membranes. (B) Tissue membranes were incubated with increasing concentrations of SR as described in the 
Materials and Methods Section. Data are mean ± SEM values of at least three independent experiments 
performed in triplicate, expressed as percent change from basal activity, binding in the absence of ligands being 
defined as 0. SR: SR141716A. 
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3.1.2  SR inhibits G-protein basal activity in cortical membranes of CB1-KO and WT 
mice  
To determine whether the effect of SR on basal [
35
S]GTPγS binding was mediated by CB1 
receptors, a range of concentrations of SR was used in membrane prepared from tissue cortex 
of WT and CB1-KO mice. As shown in Fig. 13A, SR produced a concentration-dependent 
and saturable inhibition of [
35S]GTPγS binding in the cortex of WT mice with an IC50 of 
12.56 ± 2.12 µM, and an Imax of 38% on basal activity. A similar concentration of SR, 12.66 
± 2.12 µM, was required for half-maximal inhibition of [35S]GTPγS binding in cortex of 
CB1-KO mice, as illustrated in Fig. 13B. These results demonstrated that the inhibitory effect 
of SR on basal [
35S]GTPγS binding in the mouse cortex is CB1 receptor-independent. 
A        B 
 
 
Figure 13. Effect of SR on basal [
35
S]GTPγS binding in cortical membranes of WT (A) and CB1-KO mice 
(B). Tissue membranes were incubated with 0.05 nM [
35S]GTPγS and 30 µM of GDP and increasing 
concentrations of SR as described in the Materials and Methods Section. Data are mean ± SEM values of at least 
three independent experiments performed in triplicate, expressed as percent change from basal activity, binding 
in the absence of ligands being defined as 0. CB1-KO CB1 knockout mice; SR: SR141716A.  
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3.1.3 SR inhibits basal G-protein activation in cortical membrane of GABAB-KO and 
WT mice  
To determine whether the effects of SR on basal [
35
S]GTPγS binding were mediated by other 
GPCRs mostly coupled to the inhibitory subunit Gi/o (i.e. GABAB receptors), SR 
concentration-response curves were performed in rat cortical membranes of GABAB-KO mice 
and their WT counterparts. SR reduced the basal activity of [
35S]GTPγS binding with a 
potency of 4.3 ± 1.2 μM, achieving maximal inhibition (approximately 48%) at 100 μM in 
WT mice cortical membranes (Fig. 14A). In GABAB-KO mice, non-linear regression analysis 
of SR concentration-response curve showed that maximal inhibition of basal [
35S]GTPγS 
activity was 45% and half-maximal inhibition was obtained at 3.9 ± 0.8 μM, as shown in Fig. 
14B. Thus, the inhibitory effect of SR on basal [
35S]GTPγS binding was independent from 
GABAB receptors as it was observed both in WT and GABAB-KO mice.  
 
 A            B 
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Figure 14. Effect of SR on basal [
35
S]GTPγS binding in cortical membranes of wild-type (WT) and 
GABAB-KO mice. Effect of SR141716A on basal GTPγS binding in WT (A) and in GABAB-KO (B) mice 
cortical membranes. Proteins were incubated with 0.1 nM [
35S]GTPγS and 30 µM of GDP and varying 
concentrations of SR as described in the Materials and Methods Section. Data are mean ± SEM values of at least 
three independent experiments performed in triplicate, expressed as percent change from basal activity, binding 
in the absence of ligands being defined as 0. GABAB-KO: GABAB knockout mice; SR: SR141716A. 
 
 
3.1.4 SR inhibits G protein basal activity in CHO-GABAB, CHO-D2 and in parental 
CHO-K1 cells 
Rat and mouse tissue membrane preparations contained a heterogeneous mixture of receptors, 
where receptor-receptor interactions (hetero-oligomerization, cross-talk, etc.) might occur. To 
exclude this possibility, we examined the mechanism of action of SR by using membrane 
preparations from CHO-K1 cells stable transfected either with GABAB receptors or D2 
receptors, thereby containing a homogeneous population of receptors (GABAB or D2). 
SR in a concentration-dependent manner significantly reduced the basal activity of 
[
35S]GTPγS with a potency of 8.9 ± 1.1 μM, achieving maximal inhibition (approximately 
28%) at 100 μM in CHO GABAB membranes (Fig. 15A), and a potency of  9.7 ± 4.6  μM in 
CHO-D2 membranes and at 100 μM a maximal inhibition of  15% (Fig. 15B). 
         A            B 
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Figure 15. Effect of SR on basal [
35
S]GTPγS binding in CHO-GABAB (A) and CHO-D2 membranes (B).  
SR inhibited basal GTPγS binding in CHO-GABAB (A) and CHO-D2 membranes (B). Tissue membranes were 
incubated as described in the Materials and Methods section. Data are mean ± SEM values of at least three 
independent experiments performed in triplicate, expressed as percent change from basal activity, binding in the 
absence of ligands being defined as 0. SR: SR141716A. 
 
 
Finally, to evaluate the effects of SR on G protein activity in a system devoid of receptors we 
investigated the effect of SR on [
35
S]GTPγS basal activity in not transfected parental CHO-K1 
cell membranes. According to our results in native systems, in parental CHO-K1 cells 
increasing concentrations of SR reduced the basal activity of [
35S]GTPγS with a potency of 
5.1± 1.3 μM,  reaching maximal inhibition (approximately 25%) at 100 μM (Fig. 16).  
 
 
 
Figure 16. Inhibition of basal G protein by SR using [
35
S]GTPγS binding assay in parental CHO-K1 cells. 
SR dose-dependently, saturable, and significantly reduced the basal activity of [
35S]GTPγS in a concentration 
dependent manner in parental CHO-K1 cells. Data are mean ± SEM values of at least three independent 
experiments performed in triplicate, expressed as percent change from basal activity, binding in the absence of 
ligands being defined as 0. SR: SR141716A.  
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3.1.5 Effects of SR on CB1 receptor G protein activity in [35S]GTPγS binding assay 
Consistently with a CB1 receptor agonist profile, WIN at 10 µM stimulated the binding of 
[
35S]GTPγS in rat cortical membranes up to 164% of the basal activity. This effect was 
mediated via CB1 receptors, since it was blocked by co-application of 0.1 µM of AM251 (a 
CB1 receptor antagonist-inverse agonist).  
  
 
 
Figure 17. Effects of SR on [
35S]GTPγS binding in native CB1 receptors. SR at 2.5, 10 and 25 μM was tested 
alone or in combination with WIN, a CB1 receptor agonist, or its respective competitive/inverse antagonist 
AM251, utilizing 0.05 nM [
35S]GTPγS and 30 µM of GDP in rat cortical membranes. Data are mean ± SEM of 
at least four independent experiments performed in triplicate, and expressed as percentage of basal activity, 
binding in the absence of ligands being defined as 100%. Horizontal dotted lines indicate baseline values and the 
degree of stimulation with agonist alone, respectively. Numbers above the columns represent the percentage of 
stimulation or inhibition of [
35S]GTPγS binding relative to basal activity. AM: AM251, SR, SR141716A; WIN, 
WIN55212-2.  
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SR by itself at 2.5 µM, 10 µM and 25 µM, decreased the G protein basal activity (-15%, -
23%, -30%, respectively) and this effect was not reversed by 0.1 µM of AM251 (-17%, -32%, 
35%). SR in a concentration-dependent manner antagonized the G protein stimulation induced 
by WIN 10 µM; at a concentration of 25 µM, it completely blocked the activity of G protein, 
thus acting as a CB1 receptor antagonist (Fig. 17). 
 
3.1.6 Effects of SR on GABAB and D2 receptors G protein activity in [
35S]GTPγS 
binding assay 
To evaluate whether SR inhibits G protein activity acting on different GPCRs, we performed 
[
35S]GTPγS binding assay in different tissue preparations containing various receptor 
populations, i.e. cortical, striatal rat membrane homogenates. 
As expected, baclofen at 10 µM stimulated [
35S]GTPγS binding to rat cortical membranes up 
to 43% of the basal activity. This effect was mediated via GABAB receptors, since it was 
blocked by CGP54626, a competitive antagonist of the GABAB receptor. SR itself at 2.5, 10 
and 25 µM, significantly decreased the G protein basal activity (-12%, -26%, -36%, 
respectively) and its inhibitory effect was not blocked by 30 µM of CGP54626. Unexpectedly 
SR (10 and 25 µM) also antagonized the baclofen-induced activation of G proteins (Fig. 
18A). 
As shown in Fig. 18B, quinpirole at 1 mM stimulated the binding of [
35
S]GTPγS to striatal 
membranes up to 20% of the basal activity, this effect being completely blocked by the D2 
receptor competitive antagonist  L-sulpiride (10 µM). SR alone (2.5 µM, 10 µM and 25 µM) 
and in combination with 10 µM of L-sulpiride, decreased the G protein basal activity in a 
concentration-dependent manner (-24%, -35%, -46%, respectively).  
Finally, at the highest concentration tested SR completely antagonized G-protein stimulation 
induced by quinpirole. 
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Figure 18. Effects of SR on [
35
S]GTPγS binding in native GABAB (A) and D2 (B) receptors. SR was tested 
alone or in combination with baclofen or quinpirole, respectively GABAB and D2 receptor agonists, or their 
respective competitive antagonists, CGP54626 and L-sulpiride, utilizing 0.2 nM [
35S]GTPγS and 30 µM of GDP 
in rat cortical membranes (A), and 0.1 nM [
35S]GTPγS and 300 µM of GDP in striatal membranes (B). 
Horizontal dotted lines indicate baseline values and the degree of stimulation with agonist alone. Data are mean 
± SEM of at least three independent experiments performed in triplicate, and expressed as percentage of basal 
activity, binding in the absence of ligands being defined as 100%. The numbers above the columns represent the 
percentage of stimulation or inhibition of GTPγS binding relative to basal activity. BACL: baclofen; CGP: 
CGP54626; SR: SR141716A; Quinp: quinpirole; Sulp:Sulpiride. 
 
 
3.1.7 SR inhibits agonist-stimulated [35S]GTPγS binding in rat cortical and striatal 
membranes        
The [
35S]GTPγS assay measures the level of G protein activation after agonist stimulation 
allowing to determine pharmacological ligand parameters such as potency and efficacy. 
Baclofen concentration-response curves were performed in the absence and in the presence of 
different fixed concentration of SR (0.1 µM, 1 µM and 5 µM). As shown in Fig. 19A, 
baclofen stimulated [
35S]GTPγS binding in a concentration-dependent manner with an EC50 
value of  10.26 ± 1.2 µM and a maximal stimulation of 188.3 ± 10.4%. Increasing the fixed 
concentrations of SR induced a rightward shift of the baclofen concentration-response curve 
with a concomitant significant decrease of maximal stimulation induced by baclofen. Thus, in 
the presence of 5 µM of SR, the EC50 for baclofen increased by 2-fold (23.08 ± 4.3 µM) and 
the Emax was 157.8 ± 6.7% over basal value (-17% versus Emax of baclofen). 
SR induced a more strong effect on quinpirole-stimulated [
35S]GTPγS binding in striatal 
membranes. As shown in Fig. 19B, SR (1 µM and 5 µM) significantly shifted to right the 
stimulation curve induced by quinpirole. The EC50 for quinpirole increased by approximately 
18 and 24 fold in the presence of SR at 1 µM and SR 5 µM, respectively. Moreover, the 
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maximal efficacy induced by quinpirole in the presence of 1 µM and 5 µM of SR was 
significantly (p<0.0001) reduced (122 ± 2.6% and 108 ± 2.6% over basal value).  
 
         A                                 B 
         
 
 
 
Figure 19. Effect of SR on agonist-stimulated [
35S]GTPγS binding to rat cortical (A) and striatal (B) 
membranes. Concentration-response curves for baclofen (A) and quinpirole (B) in the [
35S]GTPγS binding 
assay, in the absence () and presence of  SR  (: 0.1 µM; : 1 µM; ▼ 5 µM). (A) EC50 and Emax, baclofen: 
10.26 ± 1.2 µM and 188.3 ± 10.4%; baclofen + SR 0.1 µM: 14.96 ± 4.1 and 183.7 ± 6.9%; baclofen + SR 1 µM: 
19.5 ± 3.3 and 156.3 ± 8.9 ; baclofen + SR 5 µM: 23.08 ± 1.2 and 152.8 ± 5.7 ;  (B) EC50 and Emax, quinpirole: 
6.96 ± 1.07 µM and 134.1 ± 0.7% ; quinpirole + SR 0.1 µM: 10.86 ± 2.4  µM and 129 ± 4.2%; quinpirole + SR 
24 ± 8.6 µM and 122.4 ± 3.8%, quinpirole + SR 5 µM 70 ± 2.7 µM and 108.3 ± 1.0%. Data are from a typical 
experiment performed in triplicates, expressed as percent stimulation over basal activity, binding in the absence 
of ligands being defined as 100%. SR:SR141716A.  
 
 
Moreover, increasing concentrations of SR in the presence of fixed concentrations of baclofen 
decreased its agonistic effect with IC50 values in the micromolar range. Specifically, in the 
presence of a submaximal (10 μM) (Fig. 20A) or a saturating concentration (100 μM) of 
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baclofen  (Fig. 20B), SR inhibited baclofen-stimulated GTPγS binding with an IC50 of 11.6 ± 
1.60 µM and of 11.50 ± 1.70 µM, reaching a maximal inhibition of 58 ± 2.32% and 62 ± 
0.3%, respectively.  
 
              A                      B 
                  
 
 
Figure 20. Effects of SR on baclofen-induced [
35S]GTPγS binding in membranes from rat cortex. The 
inhibiting effect of SR was measured at two fixed concentrations of baclofen, 10 μM (A) and 100 μM (B). 
Horizontal dotted lines indicate the levels of stimulation obtained by either a submaximal (10 μM) or a saturating 
concentration (100 μM) of baclofen alone. Data are from a typical experiment performed in triplicates, expressed 
as percent inhibition of either 10 or 100 μM baclofen-stimulated [35S]GTPγS binding, being defined as 0%. 
 
 
3.1.8 SR inhibits baclofen-stimulated [35S]GTPγS binding in CB1-KO mice 
To further evaluate whether CB1 receptors mediate the effect of SR on baclofen-stimulated G 
protein activation, baclofen concentration-response curves were performed in CB1-KO mice 
cortical membranes. As shown in Fig. 21, baclofen stimulated [
35S]GTPγS binding in a 
concentration-dependent manner with an EC50 value of  6.0 ± 1.78 µM and an Emax of  143.7 
± 1.66%. In the presence of a fixed concentration of SR (5 µM) the agonistic potency of 
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baclofen was reduced by 2 fold (EC50: 9.98 ± 0.58 µM) and the efficacy decreased by 
approximately 15-20% with an Emax of 121.3 ± 1.2%, suggesting that the inhibitory effect of 
SR on G-protein activation was likely CB1 receptor–independent.  
 
 
 
Figure 21. Effect of SR on baclofen-stimulated G protein activity in cortical membranes of CB1-KO mice. 
[
35S]GTPγS binding assay was performed as described in the Materials and Methods section, utilizing 0.2 nM 
[
35S]GTPγS and 30 µM of GDP and increasing concentrations of  baclofen in the presence or absence of 5 μM 
SR. Data are mean ± SEM values of at least three independent experiments performed in triplicate, expressed as 
percent change from basal activity, binding in the absence of ligands being defined as 100. CB1-KO: CB1 
knockout mice; SR: SR141716A. 
 
 
3.1.9 Effect of SR on [3H]CGP54626 binding in rat cortical membranes 
SR up to a concentration of 1 mM failed to modify [
3
H]CGP54626 binding, whereas 
CGP54626 caused complete inhibition of the specific binding of the competitive antagonist of 
the GABAB receptor [
3
H]CGP54626 with an IC50 of 3.0 ± 0.09 nM (Fig. 22). These data 
demonstrated that SR did not bind to the orthosteric binding site of the GABAB receptors. 
Chapter 3. Results 73 
 
 
 
 
Figure 22. Displacement curves of [
3
H]CGP54626 by SR and CGP5462 in rat cortical membranes. Binding 
experiments were performed as described in the Materials and Methods section. Cortical rat membranes were 
incubated in the presence of 3 nM of [
3
H] CGP54626 (85 Ci/mM) with serial dilutions ranging from 10-11 to 10-
4 M of the unlabelled compounds. Data represent a typical experiment out of three independent experiments, 
expressed as percentage of specific binding (SB). The calculation of IC50 was performed by non-linear curve 
fitting of the concentration-effect curves using Graphpad Prism Program. The F-test was used to determine the 
best approximation of a non-linear curve fitting to one or two site model (p<0.05). SR: SR141716A. 
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3.2 Effect of SR on G protein subunits rearrangements 
 
3.2.1 SR stabilizes the constitutive state of G protein in CHO-GABAB expressing Gαo-
Rluc and Gγ2-Venus 
To understand SR molecular mechanism on G protein inhibition, BRET approach was used to 
monitor dissociation between Gαo and Gβγ subunits and their conformational rearrangements 
before and after GABAB receptors activation.  
BRET signal was measured before receptor stimulation, to observe the effect of SR on G 
protein basal activity. As shown in Fig. 23, SR increased significantly the basal BRET signal 
measured between Gαo-Rluc and Gγ2-Venus subunits, in a concentration dependent manner. 
These data suggested that SR stabilizes the constitutive formation of the Gαβγ trimer, 
independently from receptor activation. 
 
     A            B 
  
 
Figure 23. Modulation of basal BRET by SR in CHO cells expressing GABAB receptor and Gαo-Rluc, 
Flag-Gβ2 and Gγ2-Venus. (A) SR-induced changes in the basal BRET signal before GABA application, 
indicating its effect on G protein basal activity. The curves were fitted with Plateau followed by one-phase decay 
equation using Prism GraphPad software. (B) Bar graph of the change in basal BRET ratio determined in 
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experiments as in (A). Data are presented as a mean ± SEM of 6 experiments. *p<0.05, **p<0.01, 
***p<0.001,****p<0.0001 vs Control, Bonferroni test. SR: SR141716A. 
 
 
In order to evaluate the effect of SR on G protein dissociation following GABAB receptor 
activation, ΔBRET was calculated as the difference between the basal and the plateau of 
BRET signal, indicating the amount of GABAB-mediated G protein dissociation. 
During GABAB receptor activation by 10 µM of GABA, SR induced a significant decrease (at 
25 µM and 50 µM) in ΔBRET, as shown in Fig. 24. The effect of SR on the agonist-induced 
change in BRET between Gαo-Rluc and Gγ2-Venus was concentration-dependent. Taken 
together, these results indicated that SR stabilizes the G protein trimeric state and inhibited the 
molecular rearrangement between Gαo and Gβγ subunits when the GABAB receptor is 
activated.  
 
 
 
Figure 24. Modulation of signal BRET by SR in CHO cells expressing GABAB receptor and Gαo-Rluc, 
Flag-Gβ2 and Gγ2-Venus. Bar graph of the change in BRET ratio determined in experiments showed that SR 
decreased the BRET ratio during G protein activation, indicating a rearragement of Gαo-Rluc and Gγ-Venus. 
Data are presented as a mean ± SEM of 6 experiments. *p<0.05  vs GABA, Bonferroni test. SR: SR141716A. 
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3.2.2 SR induces a rearrangement between the D2 receptor and the G protein 
In order to investigate more in depth the effects of SR on the molecular interaction between 
the D2 receptor and the G protein, different constructs were created for Gαi1, with Venus tag 
inserted in connecting loops on opposite ends of the helical domains (Fig. 25). One Venus 
was inserted in the loop connecting helices A and B (Gαi1-91); the second was inserted in the 
loop connecting helices B and C (Gαi1-121). Previous studies have shown that these tags do not 
have any effect on biochemical and catalytic properties of these fusion proteins (Gales et al., 
2006). The third Venus was introduced in the linker 1 region connecting the helical and 
GTPase domains of Gαi1 subunit (Gαi1-60).  
To monitor conformational change between Gαi1 and D2 receptor, Rluc was fused to receptor 
C-terminal (Fig. 25). These positions were chosen based on the Gαβγ complex crystal 
structure and were already used in several studies (Gales et al., 2006, Ayoub et al., 2009), 
showing correct expression and efficient coupling with different receptors.  
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Figure 25. Schematic representation of G protein and receptor BRET fusion proteins. Rluc probe in D2 
receptor is shown in blue and Venus probes on G αi1 subunits are shown in yellow. 
 
 
Basal BRET signal was detected between the D2 receptor (D2-Rluc) and each of Gαi1-Venus 
protein subunits (Gαi1-60, Gαi1-91 and Gαi1-121), after 1h incubation of SR. 
As shown in Fig. 26, SR increased BRET signal between D2-Rluc and Gαi1-91-Venus and 
between D2-Rluc and Gαi1-121-Venus. However, no effect was observed between D2-Rluc and 
Gαi1-60-Venus in the presence of SR (25 µM). This lack of changes in the BRET signal did not 
result from disruption of fusion protein activity, since quinpirole application induced G 
protein dissociation detected for all of three different constructs, confirming their 
functionality.  Moreover, differences in the basal BRET signal between all of three fusion 
proteins were not due to the difference in the expression level quantified by fluorescence 
measurements. 
Using this model, the changes in the basal BRET signal observed with SR might reflect a 
rearrangement on constitutive receptor-Gαβγ complex, which is consistent with the increase 
in basal BRET observed between Gαo-Rluc and Gγ2-Venus.  
Together, the SR-promoted BRET changes support the hypothesis that the Gα subunit might 
be the direct target of this compound. 
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Figure 26. Effect of SR on Gαi1 subunit and D2 receptor rearrangement. Differences in BRET signals 
observed between specified Gαi1 subunits and D2 receptor, in the presence and absence of 25 µM of SR. Data 
are presented as a mean ± SEM of 5 experiments. **p<0.01 vs Gi91 Ctr, 
####
p<0.0001 vs Gi121 Ctr, Bonferroni 
test.  
 
 
3.3.2 SR induces a conformational change on G protein subunits independently from 
the receptor 
To investigate whether SR can induce BRET changes between G protein subunits 
independently from the receptor, other constructs were used. The Rluc tag was inserted in the 
C-terminal of Gβ and Gγ subunits (Fig. 27). The introduction of these new tags in Gβγ dimer 
has been shown not to affect its functional properties (Gales et al., 2006).   
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Figure 27. Schematic representation of the different tags on the G protein subunits. Rluc probes in Gβ and 
in Gγ C-terminal are shown in blue and Venus probes on Gαi1 subunit are shown in yellow. 
 
 
BRET signal was detect between Gαi1 protein subunits (Gαi1-60-Venus, Gαi1-91-Venus and 
Gαi1-121-Venus) and Gβ1-Rluc or Gγ2-Rluc subunits after 1h incubation of SR. 
As shown in Fig. 28A, SR significantly increased BRET signal between Gβ1-Rluc and Gαi1-
91Venus, and between Gβ1-Rluc and Gαi1-121-Venus. Similar results were obtained measuring 
the basal BRET signal between Gαi1-91-Venus or Gαi1-121-Venus and Gγ2-Rluc (Fig. 28B).  
As previously observed using Rluc tag on D2 receptor, no effect was detected between Gαi1-
60-Venus and Gβ1-Rluc or Gγ2-Rluc in the presence of SR (25 µM).  
The BRET changes monitored when using Gαi1-91-Venus and Gαi1-121-Venus as BRET 
acceptors probably reflect a SR-promoted conformational rearrangement within Gαβγ 
complex that is differentially monitored depending on the acceptor and donor position.  
The absence of change in the BRET signal using the Gαi1-60Venus might be due to a possible 
interaction between SR and the linker 1 region, leading to a different movement of α helical. 
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These results confirm that SR induced conformational changes in the G protein heterotrimeric 
conformation independently from the receptor, suggesting that the Gα subunit might be the 
direct target of this compound, inducing rearrangement in the α-helical domain.  
 
 
     A         B 
 
 
Figure 28. Effect of SR on Gαi1 subunit and Gβγ rearrangement. Differences in BRET signals observed 
between specified Gαi1 and Gβ subunits (A) and Gγ (B) in the presence and absence of 25 µM of SR. (B) Data 
are presented as a mean ± SEM of 5 experiments. **p<0.01 vs Gi91 CTR, 
###
p<0.001 vs Gai121 CTR, *p<0.05 
vs Gai91 Ctr, 
#
 p<0.05 vs  Gai121 CTR, Bonferroni test. 
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3.3 Effects of SR on G protein subunits effectors 
 
3.3.1 SR inhibits the agonist-mediated inhibition of Adenylate Cyclase activity  
Recently, detection of the intracellular cAMP in vivo is become possible using BRET assay. 
Jiang et al. (2007) developed a sensor, known as CAMYEL (cAMP sensor using YFP-Epac-
RLuc) that can be used to monitor cAMP intracellular formation in real time. Previous studies 
have employed this sensor to characterize distinct pathways, which modulate cAMP synthesis 
stimulated by Gs receptors.  
Here, to identify whether SR induces effects on Gαi/o and/or Gαs protein pathway, CAMYEL 
sensor was transiently transfected together with GABAB, dopamine D2, or dopamine D1 
receptor. Changes in BRET ratio are used to continuously monitor intracellular cAMP in real 
time in living cells. First, forskolin application activates adenylate cyclase leading to a rapid 
elevation of cyclic cAMP that binds to CAMYEL. This leads to a conformational change 
resulting in a decrease of BRET signal.  
The BRET signal was detected before and after GABAB receptor activation, induced by 
injection of GABA (100 µM). As expected GABA (100 μM) reverted the decrease of BRET 
signal induced by forskolin, indicating an inhibition of cAMP forskolin-induced. Importantly, 
SR at 50 µM decreased the GABA-induced BRET signal, attenuating the GABA inhibitory 
effect (Fig. 29A). Moreover, SR (25 and 50 µM) decreased significantly the tau of CAMYEL 
activation, which indicates a faster CAMYEL activation, and reduced ΔBRET. These results 
suggest that SR inhibited G proteins activation induced by GABAB receptors (Fig. 29, panels 
B and C). 
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Figure 29. Effects of SR on CAMYEL activity in HEK293-GABAB. (A) HEK293 cells transiently transfected 
with CAMYEL and GABAB receptor were incubated with SR (25 µM and 50 µM) for 1 h a 37°C. BRET 
measurements were performed after the addition of the substrate. Data represent the BRET ratio of YFP/Rluc for 
control and SR under GABA-stimulation conditions. The curves were fitted with One-phase association equation 
using Prism GraphPad software. (B) Bar graph of the amplitude-weighted mean time constant (tau CAMYEL 
activity) showed that SR increased CAMYEL activation, expressed as decrease of tau CAMYEL activity. Data 
are presented as a mean ± SEM of 5 experiments. *p<0.05 vs GABA, Bonferroni test. (C) Bar graph showed that 
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SR decreased the ΔBRET, calculated as the difference between the basal and the plateau of BRET signal. Data 
are presented as a mean ± SEM of 5 experiments. *p<0.05, **p<0.01, ***p<0.001vs GABA, Bonferroni test. 
SR: SR141716A. 
 
 
As regard the D2 receptor, its agonist quinpirole stimulated the receptor thereby activating 
Gαi/o protein that inhibited the adenylate cyclase resulting in a decreased CAMYEL activity. 
After injection of quinpirole (10 µM), SR increased CAMYEL activation, expressed as 
decrease of tau CAMYEL activity, and decreased ΔBRET. Taken together these results 
showed that SR blocked the inhibitory effect of Gi/o-protein on cAMP production resulting in 
increase of CAMYEL activation (Fig. 30).  
 
A       B 
 
 
Figure 30. Effects of SR on CAMYEL activity in HEK293-D2. HEK293 cells transiently transfected with 
CAMYEL and D2 were incubated with SR (25 µM and 50 µM) for 1 h a 37°C. BRET measurements were 
performed after the addition of the substrate. (A) Bar graph of the amplitude-weighted mean time constant (tau 
CAMYEL activity) showed that SR increased CAMYEL activation, expressed as decrease of tau CAMYEL 
activity. Data are presented as a mean ± SEM of 5 experiments. *p<0.05 vs quinpirole, Bonferroni test. (B) Bar 
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graph showed that SR decreased the ΔBRET, calculated as the difference between the basal and the plateau of 
BRET signal. Data are presented as a mean ± SEM of 5 experiments. **p<0.001 vs quinpirole, Bonferroni test. 
 
 
In the same way, we evaluated the effect of SR on Gs-coupled receptor stimulation. For this 
purpose, D1 receptor, which is coupled to Gs-protein, was transfected with CAMYEL, and the 
BRET signal was detected after dopamine injection.    
As shown in Fig. 31, dopamine decreased the BRET signal through increase of cAMP and 
activation of CAMYEL sensor. In the presence of SR (50 µM), no effect was observed in the 
BRET signal, indicating that SR did not interact with Gαs subunit.  
 
 
 
Figure 31. Effects of SR on CAMYEL activity in HEK293-D1. HEK293 cells transiently transfected with 
CAMYEL and D1 receptor were incubated with SR (50 µM) for 1 h a 37°C. BRET measurements were 
performed after the addition of the substrate. Data represent the BRET ratio of YFP/Rluc for control and SR 
under agonist-stimulation conditions. The curves were fitted with Plateau followed by one-phase decay equation 
using Prism GraphPad software. SR: SR141716A. 
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3.3.2 SR blocks GIRK channel activity in VTA slices 
Whole cell voltage clamp recordings from midbrain dopamine neurons in acute rat brain 
slices ex vivo were performed to evaluate the effects of SR on baclofen and quinpirole-
induced outward K
+
 current. In order to establish whether SR acts independently from CB1 
receptors, experiments were carried out using CB1-WT and -KO mice. As shown in Fig. 32A, 
baclofen application (10 µM) induced outward GIRK current activated by the GABAB 
receptor. However, when the slice was treated with SR (10 µM), baclofen induced current was 
completely blocked (Fig. 32B). Moreover, when D2 receptor was activated by quinpirole (1 
µM), SR treatment (10 µM) blocked the D2-induced current as well (Fig. 32C).   
Thereafter, to confirm that the blocking of GABAB-mediated current is independent of CB1 
receptor, CB1-KO mice were used. The CB1 receptor was not required for SR inhibition of 
GABAB induced current, since SR treatment blocked the GABAB-induced GIRK current in 
CB1-KO mice similarly to the WT mice (Fig. 32D). These results demonstrate that by 
inhibiting G protein activation, SR blocked Gβγ effector systems, such as GIRK channel 
activation, and that this effect was not CB1 receptor mediated. 
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Figure 32. SR blocks baclofen- and quinpirole- induced outward current in dopamine neurons via a 
mechanism independent from CB1 receptor activation. Time course graphs illustrate the average effects of 
baclofen (10 μM, A-B-D), quinpirole (1 μM, C) and SR 10 μM (B-C-D) on holding current (Ihold) of dopamine 
cells. BACL: baclofen; QUINP: quinpirole; SR: SR141716A; VEH: vehicle. 
 
 
3.3.3 SR decreases GIRK channel activity in the absence of GPCRs 
In order to evaluate whether SR blocks GIRK activation by directly acting at the G protein, 
whole cell patch clamp recordings were performed in CHO cells transiently transfected with 
Kir 3.1/3.2. For this purpose, GIRKs were activated in a receptor-independent manner with 
the non-hydrolysable GTP-analog guanosine, 5’-O-(3-thiotriphosphate) (GTPγS), perfused 
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into the cell via the recording pipette (Fig. 33A). By exchanging for GDP at Gα, GTPγS 
liberates Gβγ and constitutively activates GIRKs. In the absence of SR, GTPγS induced 
inwardly rectifying K
+
 currents that exhibited modest desensitization over the 10 min 
recording period (Fig. 33A). In contrast, in the presence of SR (10 μM) the currents were 
significantly smaller. As shown in Fig. 33B, SR at 10 μM decreases the amplitude of K+ 
current and increases the rise time of GIRK channel. In agreement with the BRET 
experiments, these data suggest that SR directly affects Gαi/o proteins, stabilizing their 
heterotrimeric state and blocking the G protein signaling in living cells. 
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Figure 33. Effect of SR on GIRK activation in CHO cells. (A) Representative K
+
 current activated by 
intracellular perfusion of GTPγS (0.6 mM) and recorded at -50 mV in transfected CHO cells expressing GIRK 
1/2 channels. (B) Bar Graph summarizes the relative effects of SR on GTPγS-induced responses. Data are 
presented as a mean ± SEM of 4 experiments and Statistical significance was assessed using a paired Student’s t-
test (***p<0.001). 
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Chapter 4. Discussion 
 
In this study, we investigated the molecular mechanisms of SR on G protein activity in native 
and recombinant systems by combining different experimental approaches, i.e GTPγS, BRET, 
and electrophysiological recordings.  
The main finding is that SR, at micromolar concentrations, prevented GPCR-G protein 
signaling through a direct interaction with G proteins, mostly with αi/o subunits.  
Specifically, we showed that SR (i) inhibited G protein basal activity in native and 
recombinant systems independently of the presence of GPCRs, (ii) attenuated G-protein 
activation produced by GABAB and D2 receptor agonists via the CB1 receptor-independent 
mechanism, (iii) stabilized the constitutive state of G-protein and (iv) induced a 
rearrangement of Gα and Gβγ subunits. Moreover, SR suppressed both GABAB and the D2 
receptor-activated inwardly rectifying K
+
 currents in VTA dopamine cells, and prevented a 
GTPγS-induced response on GIRK activation in CHO cells. 
By using ligand-modulated [
35S]GTPγS binding, which allows both the investigation of drug 
actions directly at the level of the G-protein and the evaluation of spontaneous receptor 
activity by monitoring the levels of basal [
35S]GTPγS binding, we found that SR decreased 
basal [
35S]GTPγS binding to striatal and cortical membranes of rats and to cortical membranes 
of wild-type mice, CB1 receptor- and GABAB receptor-KO mice. Moreover, a SR-induced 
decrease of basal  [
35S]GTPγS binding was not prevented by co-application of CB1, GABAB 
and D2 receptor antagonists. The efficacy and potency of SR in inhibiting G protein basal 
activity were similar in rat and mouse brain tissues obtained from WT animals or mice 
lacking either CB1 or GABAB receptors. Specifically, SR inhibited in a concentration-
dependent manner the basal activity of  [
35S]GTPγS binding with IC50 of 3.8 ± 0.45 μM,  
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12.56 ± 2.0 μM, 12.66 ± 2.1 μM and 3.9 ± 0.8 μM in the cortex of rats, wild-type mouse, 
CB1-KO and GABAB-KO mice, respectively. The percentage of maximal inhibition (Imax) of 
basal activity ranged from -36 to -48% with respect to basal activity (considered as 100%) in 
all tissue preparations.     
Our findings confirm and extend previous data showing that at high concentration (μM) SR 
behaves as an “inverse agonist” (see Pertwee 2005 for a review). The reduction of 
[
35S]GTPγS binding by SR has been previously described in rat, mouse and human tissues 
(Sim-Selley, 2003; Savinainen et al. 2003; Breivogel et al., 2001; Erdozain et al., 2012) as 
well as in heterologous expression systems (MacLennan, 1998) and in cultured rat brain 
(Breivogel et al., 2004).  
Furthermore, our results support the evidence that SR effects on basal G protein activity are 
independent not only from CB1 receptors but also from other GPCRs, such as GABAB 
receptors, whose signaling is mediated (as for the CB1 receptor) mainly by the G protein 
subunit Gi/o.  
Indeed, we showed that SR decreased G protein basal activity in cell lines containing a 
homogenous population of either GABAB (CHO-GABAB) or D2 (CHO-D2) receptors, 
thereby excluding that receptor interactions, such as hetero-oligomerization or cross-talk, 
might influence the action of SR. Moreover, we demonstrated that the extent of the inhibitory 
effect on G-protein signaling was very similar in the CHO- GABAB, CHO-D2 and the 
parental CHO-K1 cell membranes, which supports the possibility that SR might act in a 
receptor-independent manner. The degree of SR-induced decrease of basal G protein activity 
(approximately 25%) in both cells expressing GPCRs and non transfected CHO-K1 cells was 
lower than that observed in mouse and rat tissue membranes. One possible explanation may 
be represented by the lower amount of endogenous Gi2 and Gi3 protein subtypes present in 
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CHO cells (approximately 5 pmol/mg and 0.6 pmol/mg, respectively) (Raymond et al., 1993; 
Gettys et al., 1994) compared with native systems such as rat, mouse and human tissue 
membranes.  
It has been previously reported that SR may act as an “inverse agonist” toward other GPCRs. 
For example, Cinar et al. (2009) demonstrated that in CHO stable cells transfected with 
MORs, the specific MOR agonist DAMGO stimulated [
35S]GTPγS binding that was inhibited 
by 10 μM SR. In addition, SR binds directly to MORs, albeit with low affinity, and modulates 
their signaling in mouse cortex and MOR-CHO membranes (Cinar and Szucs, 2009). 
Recently, it was shown that the CB1 receptor antagonist/inverse agonist AM251 and SR bind 
with mid-nanomolar concentration to human MORs and competitively antagonize morphine-
induced G-protein activation in CHO-hMOR cell homogenates (Seely et al., 2012). The same 
authors also demonstrated a cross-inhibition of G-protein signaling between GABAB and CB1 
receptors in hippocampal membranes (Cinar et al., 2008).  
Recently, Erdozain et al. (2012) evaluated which G protein subunits are activated by CB1 
receptors using an antibody-capture [
35S]GTPγS scintillation proximity assay (SPA), coupled 
with immunoprecipitation with a specific antibody for different Gα subunits. Thanks to this 
assay, which permits the determination of receptor-mediated activation of specific G-protein 
families, the authors showed that in post-mortem human brain cortical membranes WIN (10 
μM) produced a significant stimulation of the GTPγS binding mediated by Gαi1, Gαi2, Gαi3 and 
Go, but not Gq/11, Gs/olf or Gz, this stimulation being constantly blocked by the CB1 receptor 
neutral antagonist O-2050 and SR. Moreover, 10 μM SR inhibited SPA-[35S]GTPγS binding 
when specific anti- Gi3, Go, and  Gz antibodies were used, an effect not prevented by O-2050. 
Based on these premises, we evaluated whether SR affects the agonist-stimulated [
35S]GTPγS 
binding mediated by GABAB and D2 receptors, which share almost the same pool of G 
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inhibitory proteins, by using different tissue membrane preparations.  
Our data revealed that SR, other than CB1, also modulates GABAB and D2 receptor signaling. 
SR attenuated the activation of  [
35S]GTPγS binding to cortical and striatal membranes 
produced by the GABAB receptor agonist baclofen and the D2 receptor agonist quinpirole, an 
effect not blocked by the respective specific antagonists CGP54626 and sulpiride. Moreover, 
in our native system SR competitively antagonized G protein activation by the two agonists, 
baclofen and quinpirole. Specifically, co-incubation with SR (5 μM) resulted in a 2-fold 
reduction of the potency of baclofen to activate G protein with a concomitant significant 
reduction of its efficacy. Similarly, co-incubation of quinpirole with equal and lower 
concentrations of SR (1 and 5 μM) induced a greater reduction of potency (18 and 24 fold at 1 
and 5 μM, respectively) and a significant reduction of efficacy of quinpirole-stimulated G 
protein activity. Moreover, SR at a micromolar concentrations inhibited the G protein activity 
induced by both submaximal and saturating concentrations of baclofen. Finally, by using a 
radioligand competition binding assay in cortical membranes, we showed that SR did not 
interact with the ortosteric site of GABAB receptor, confirming that its effects on baclofen-
stimulation were GABAB receptor-independent. 
Collectively, these findings indicate that SR effects on both basal and agonist-stimulated G 
protein activity are independent from all GCPRs receptor tested, suggesting that SR might act 
directly on G protein activity.  
Indeed, SR is a highly hydrophobic molecule, thus able to cross the cell membrane and exert a 
multitude of effects directly on the G protein subunits. To investigate whether this compound 
might act directly on the G protein heterotrimer complex, we used a recently described BRET 
approach that allowed the direct monitoring of G protein activation (Ayoub et al., 2009; Gales 
et al., 2006).  
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First, by using BRET measurements between Gαo-Rluc and Gγ2-Venus in CHO-GABAB 
transfected cells, we showed that SR increased the basal BRET signal between the Gαo and 
Gγ2 subunits significantly in a concentration-dependent manner. SR induced a strong effect on 
the G protein constitutive state by increasing the Gαβγ heterotrimeric complex, independently 
from receptor activation.  
These data are consistent with our [
35
S]GTPγS results, which showed a decrease of basal G 
protein activity in a receptor-independent manner. Moreover, once the GABAB receptor is 
activated SR significantly reduces the GABA-induced changes in BRET signals between Gαo-
Rluc and Gγ2-Venus. These findings demonstrated that SR decreased the dissociation of G 
protein subunits (i.e Gαo and Gβγ) after GABAB receptor activation, promoting a preassembly 
within the GABAB receptor and G protein subunits.   
In the last years, several studies have used agonist-promoted BRET changes as a readout of 
protein transition states, such as G protein subunit dissociation, while others have explained 
these changes as a molecular rearrangement within the Gαβγ complex.  
By using a crystal model it has been shown that structural differences observed between 
active and inactive conformers are relatively modest, and involve only switch I, II and III 
regions of the Gα subunits, which are crucial in guanine nucleotide exchange (Noel et al., 
1993). 
However, by using multiple insertion sites for BRET donors and acceptors it was possible to 
monitor real-time ligand-promoted conformational changes between receptor and G protein 
and Gαβγ subunits in living cells. Gales et al. (2006) have also shown that, in the absence of 
an agonist, a fraction of the adrenergic α2A receptor exists in a pre-associated complex with G 
protein. Indeed, a basal BRET signal between receptor and Gαβγ subunits was observed 
before agonist stimulation.  
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Accordingly, SR was found to increase the basal BRET signal within D2 receptors tagged 
with Rluc and Gαi1 tagged with Venus in three different positions. Depending on the position 
of the probes, SR increased the BRET signal reflecting a pre-associated receptor-G-protein 
complex rather than effects on Gαi1 subunit recruitment. Detection of different BRET signals 
between Gαi1-91Venus, Gαi1-121Venus and the D2 receptor indicated that SR induces a re-
arrangement on α-helical domain, affecting the interactions between the receptor and the Gα 
subunits.   
Finally, our findings demonstrated that SR directly interacts with the Gα subunit inducing 
conformational changes within the Gαβγ trimeric complex in a receptor-independent manner. 
This conclusion is supported by the increase in the BRET signal induced by SR and detected 
between Gαi1-91Venus and Gαi1-121Venus and Gβ1 or Gγ2-Rluc fusion proteins.  
In this study, the position of BRET donors and acceptors allowed us to monitor the relative 
movement between the Gαi1 and both Gγ2 and Gβ1 subunits. We found that SR increased the 
BRET signal for both Gαi1-91Venus and Gαi1-121Venus detected with Gβ1-Rluc, and Gγ2-Rluc. 
No effects were observed in the BRET signal monitored between Gαi1-60Venus and Gβ1-Rluc, 
Gγ2-Rluc and D2-Rluc. These findings have lead us to speculate that the mutation in the 
linker 1 region in the Gαi1-60Venus fusion protein might disrupt the SR binding site. SR 
induced changes in the BRET signal was detected for all fusion proteins rather than when 
Gαi1-60Venus was used.   
The linker 1 region acts as a hinge during the opening of the α-helical domain, allowing the 
necessary route for GDP to leave the GTPase domain. The absence of changes in the BRET 
signal detected using Gαi1-60Venus, which is situated in the linker 1, in the presence of SR 
supports the hypothesis that SR might bind to Gα subunits by keeping the α helical domain in 
the inactive conformation and thus decreasing GDP/GTP exchange. 
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In addition, the “gear-shift” model (Cherfils and Chambre, 2003) proposes that receptor 
activation promotes the strength of interaction between the β propeller region of the Gβ 
subunit and the GTPase domain in the nucleotide-empty state. Our results suggest that SR 
blocks the displacement of the α-helical domain away from the GTPase region by inhibiting 
the dissociation between the Gα subunit and the Gβγ dimer. This hypothesis is consistent with 
the increase of the BRET signal monitored in the presence of SR between Gβ1-Rluc or Gγ2-
Rluc and both of Gαi1-Venus (91 and 121 position). 
Further, this suggestion reflects a common structural re-arrangement that might be 
characteristic of a G protein constitutive state. Indeed, crystal structures of the GTPase 
domain have revealed that only local changes are involved in the nucleotide binding (Noel et 
al., 1993).  
The conformational change induced by SR on Gαi1 and Gαo subunits might directly affect the 
molecular mechanism of G protein basal activity and its activation.    
Next, we evaluated the effects of SR on adenylate cyclase activity, using BRET with the 
CAMYEL sensor, a recent technique developed to detect the level of cAMP in living cells. 
We investigated the inhibitory effects of SR on Gi and Gs protein pathways by measuring the 
BRET signal in cells transfected with CAMYEL and GABAB, D2 or D1 receptors. 
First, we showed that SR, which did not stimulate cAMP by itself, increases the level of 
cAMP after the injection of baclofen or quinpirole, suggesting that SR inhibited the Gαi/o 
pathway. Indeed, the Gα subunit is involved in regulating adenylate cyclase activity, while the 
activation of GPCRs affects intracellular cAMP levels.  
Stimulation of receptors coupled with the Gαi/o subunit decreases cAMP and this effect is 
inhibited by SR. Conversely, stimulation of receptors coupled with the Gαs subunit increases 
cAMP. No effects are observed on cAMP levels regulated by the injection of dopamine in 
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cells expressing the D1 receptor.  
Previous studies have found that SR increases Forskolin-stimulated cAMP in CHO-CB1 cells 
and in neuroblastoma cells (Bouaboula et al., 1997; Meschler et al., 2000), and enhances basal 
cAMP levels in rat and human frontal cortical and cerebellar membranes (Mato et al., 2002). 
These effects were explained as the antagonist/inverse agonist effects of SR on CB1 
receptors. 
In contrast, our results show that the effects of SR on cAMP regulation via the Gαi/o pathway 
are not linked to the CB1 receptor, since they were observed in HEK293 cells transfected with 
the GABAB or D2 receptor. 
Furthermore, these effects are probably specific to Gαi/o subunits, since increased cAMP 
induced by D1 receptor stimulation was not affected in the presence of the highest 
concentration of SR.  
Finally, using an electrophysiological approach, we showed that SR inhibited the G protein-
mediated K
+
 current induced by baclofen and quinpirole in dopamine neurons of CB1-WT 
and KO mice. SR also blocked the G protein-mediated K
+
 current induced by GTPγS in CHO 
cells transfected with GIRK1/2.  
The CB1 receptor regulates the activity of Ca
2+
 and K
+
 channels. Previous studies showed that 
SR increased voltage-dependent Ca
2+ 
current in CB1-expressing rat cultured neurons and 
cultured pelvic ganglion neurons (Pan et al., 1998), suggesting that SR affects Ca
2+ 
activity by 
blocking the CB1 receptor in the “receptor-G protein-GDP” state.  
Our results revealed that SR blocks GIRK channel activity independently of CB1 receptors in 
VTA dopamine cells. Particularly, whole cell patch clamp experiments showed that GIRK 
currents produced by baclofen or quinpirole were significantly reduced by SR. Moreover, a 
complete blockade of GIRK currents by SR (10 µM) in the VTA dopamine cell was also 
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reported in CB1-KO mice, thus suggesting that SR inhibits GIRK currents in a CB1 receptor-
independent manner. 
Finally, using a GPCR-free experimental setup, i.e. whole cell patch clamp experiments 
performed in CHO cells transfected with GIRK1/2 only, we showed that SR induces the 
inhibition of GIRK channel activity by acting directly on G protein. We found that SR inhibits 
GTPγS-mediated GIRK currents thus decreasing the current amplitude and increasing the rise 
time of the channel.  
Taken together, these data suggest that SR interacts directly with G protein subunits and 
inhibits the Gβγ dissociation and its effectors system. 
Our current hypothesis is that SR might bind to the G protein, stabilize the Gαβγ complex, 
and thus affect cAMP production and GIRK channel activity. Hence, several effector systems 
are regulated by Gi/o protein-activation. In the presence of a micromolar concentration of SR 
we found a decrease in GDP/GTP exchange and K
+
 current and an increase in intracellular 
levels of cAMP. These effects might all be correlated with a negative modulation induced by 
SR on the G-protein, both in its constitutive and activated form.  
In conclusion, altogether our findings support the hypothesis that, at least at micromolar 
concentrations,  SR might act directly on the G protein mostly with αi/o subunits. 
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Conclusions 
 
This study provides the first demonstration that the commonly employed CB1 receptor 
antagonist SR, at micromolar concentration, inhibits G protein activity and blocks different 
signal pathways in a receptor-independent manner. As such, multiple effects on G protein 
signaling resulting from a high concentration of SR should be carefully interpreted.  
GPCRs have a relevant function in various diseases, including metabolic, neurodegenerative 
and psychiatric disorders. They are also involved in cell proliferation and thus play a key role 
in tumor growth. Tumor cell proliferation is regulated by several neuropeptides that activate 
their receptors, stimulate Gαs, Gαi, Gαq and Gα12 and regulate the nuclear expression of 
growth-promoting genes (Dorsam and Gutkind, 2007). Importantly, constitutive activation of 
a mutated form of GPCRs or G proteins is associated with endocrine tumors (Dorsam and 
Gutkind, 2007).  
Recently, G protein inhibitors or antagonists, interacting with Gβγ subunits or stabilizing 
Gαβγ complex, have shown antitumor activity in animal models (Bonacci et al., 2006). 
Additional evidence that modulations of G protein signaling may represent a new therapeutic 
strategy for treating cancer come from Prévost et al. (2006). They found that a molecule, 
named BIM-46174, shows anticancer activity by inducing a conformational change on the G 
protein heterotrimeric complex thus blocking GPCR activation. 
Previous studies showed that SR exerted anti-proliferative effects in human peripheral blood 
cells, blocking the G1/S phase of the cell cycle without inducting cell death (Malfitano et al., 
2008).  
In this study, we found that SR inhibited basal and agonist-stimulated G protein activity, 
increased the Gαβγ heterotrimeric state, and induced a conformational rearrangement between 
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G protein subunits.  
Our data highlight that SR can be a potential specific-inhibitor of heterotrimeric Gi/o proteins.  
More importantly, SR might bind to linker 1 region on the Gαi/o subunit, thus representing a 
possible tool for developing new drugs for simultaneous Gi/o protein inhibition.  
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List of abbreviations 
 
 
 
2-AG  2-arachinoyl-glycerol 
2-AGE 2-arachidonyl-glyceryl ether 
AD  adenylate cyclase  
ADP  adenosine diphophate  
AEA  N-arachinodil-ethanolamine 
ATP  adenosine triphosphate  
BRET  Bioluminescence resonance energy transfer 
cAMP  cyclic-adenosine 3’,5’-monophosphate  
CAMYEL cAMP sensor using YFP-Epac-Rluc 
CB1  cannabinoid receptor type 1 
CB2  cannabinoid receptor type 2 
CHO  Chinese hamster ovary 
CNS  central nervous system 
DAMGO Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol 
DOR  δ opioid receptor 
EC  endocannabinoids 
EC  extracellular loops  
ECS  Endocannabinoid system 
FAAH  Fatty Acid Amide Hydrolase 
FDA  Food and Drug Administration 
G protein guanine-nucleotide binding protein  
GDP  guanosine diphosphate  
GEF  guanine nucleotide exchange factor  
GIRK   G protein-activated rectifying K
+
 channel 
GPCR  G-protein-coupled receptor  
GRK  G protein-coupled receptor kinase  
GTP   guanosine thriphosphate  
HU-210 11-hydroxy-Δ8-THC-dimethy-pentyl 
 List of abbreviations 103 
IC  intracellular domains  
KO  knock out 
LT  leukotrienes 
LX  lipoxins 
MAGL monoacylglycerol lipase 
MAPK mitogen-activated protein kinase 
MOR  µ opioid receptor 
NADA N-arachidonoyl-dopamine 
PG  prostaglandins 
PKA  cAMP-dependent protein kinase  
PKC  protein kinase C  
PLC  phospholipase C  
RGS  regulator of G protein signalling  
Rluc   Renilla luciferase 
SR  SR141716A 
THC  (-)-Δ9-tethrahydrocannabinol 
TM  transmembrane domains   
TRPV1 Vanilloid 1 receptor 
TX  thromboxanes  
WIN  R-(+)-WIN55212 
WT  wild type 
YFP   yellow fluorescence protein 
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